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1. Abstract 
 
A novel negative regulatory pathway of T-cell activation has been recently 
described, involving the scaffold protein SRC homology 2 (SH2)-domain-containing 
leukocyte protein of 76 kDa (SLP76) and the Hematopoietic progenitor kinase 1 
(HPK1). It was shown that a single point mutation on SLP76 (S376A) prevents 
phosphorylation of this protein by HPK1 and impairs the negative regulation of T-cell 
activation, thus rendering T-cells more sensitive to activating stimuli.  
SLP76 is a major component of a signaling platform assembled upon antigen 
recognition by T-cells. Hence, SLP76 influences various processes including: T-cell 
survival, proliferation, maturation and differentiation. Furthermore, SLP76 has been 
reported to be essential for T-cell development. 
A SLP76-S376A mutant mouse model has been generated to investigate the 
physiological consequences of impairing the negative regulatory pathway mentioned 
above. One of the aims of this Master Thesis was to characterize these SLP76-
S376A mutant mice, focusing in particular on the effects of the mutation on early 
TCR-mediated signaling and downstream effector functions of mature T-cells, as well 
as on thymic T-cell development,  
Our results indicate that SLP76-S376A mice do not exhibit significant defects 
in T-cell development, in line with previous reports with HPK1 knock-out mice. 
However, we demonstrated that TCR-stimulation induced higher Extracellular signal-
regulated kinases (ERKs) phosphorylation in SLP76-S376A peripheral T-cells 
compared to wild type cells. Moreover, we observed higher proliferation rates for 
SLP76-S376A mutant CD4+ and CD8+ T-cells, as well as increased INF-γ 
production for SLP76-S376A mutant CD8+ T-cells. Collectively, these data suggest 
that SLP76-S376A mice display a set of altered T-cell properties most likely 
dependent on a defective negative regulation of TCR-induced signaling. 
Recent data demonstrating increased T-cell-dependent anti-tumor immunity in 
HPK1 knock-out mice (Alzabin et al., 2010), suggest that SLP76-S376A mice may be 
an optimal tool for investigating whether the negative regulatory function of HPK1 is 
responsible for its ability to control anti-tumor T-cell responses . Therefore, I also 
developed and validated a bioluminescent cancer cell line that will be useful to 
address the importance of the HPK1-SLP76 pathway in anti-tumor immunity. 
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2. Introduction 
 
2.1. Overview – T cell development: maturation and differentiation 
 
This introduction will present an overview of development and functions of T 
lymphocytes, focusing in particular on CD4+ and CD8+ T-cells. The aim of this section is to 
provide a general framework to understand the physiological relevance of the work described 
in this master thesis. A more detailed description of TCR-dependent signaling pathways and 
of the particular mutant mouse model used in our studies will be provided in order to 
understand the scientific questions we asked and the approaches used to address them. 
 
All the cellular elements of blood derive from precursors found in the bone 
marrow (Figure 1), called hematopoietic stem cells (HSCs). HSCs are pluripotent and 
give rise to cells with more limited developmental potential called common myeloid 
progenitor (CMP) and common lymphoid progenitor (CLP). CMPs give rise to red 
blood cells, platelets and leukocytes of the innate immune system e.g.: mast cells, 
macrophages and granulocytes. On the other hand, CLPs give rise to B-cells, T-cells 
and natural killer (NK)-cells. The first two CLP derived cell types belong to the 
adaptive immune system, whereas NK-cells are classified as innate immune cells. 
With regard to this work, the focus will be set on immune cells of the adaptive 
immune system, concentrating particularly on T-lymphocytes. 
 
Figure 1 
Hematopoiesis. 
Hematopoietic stem cells 
give rise to two major 
progenitor cell lineages, 
myeloid and lymphoid 
progenitors (Regenerative 
Medicine, 2006)  
 
http://www.allthingsstemcell.com/wp-content/uploads/2010/02/Hematopoiesis_simple_reprogramming1.png 
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The adaptive immune system is a highly developed network of cells, which 
recognizes and fights pathogens, toxins or other threatens. These potential dangers 
are identified based on their expression of “non-self antigens”, e.g. elements that are 
not present in the human body under normal conditions, therefore being unknown to 
immune cells. In contrast to the innate immune system, the adaptive immune system 
has the ability to recognize antigens in a highly specific manner. This is achieved by 
creating high affinity interactions between membrane-bound receptors or soluble 
proteins (antibodies), expressed by immune cells, and antigens. Another important 
attribute of the adaptive immune system is the capability of keeping an 
“immunological memory” of previously encountered antigens, enabling a faster and 
more efficient response upon secondary infections by the same pathogen. 
 
As mentioned above, T-Lymphocytes develop from CLPs that derive from 
HSCs. These CLPs have the potential to give rise to either B- or T-Lymphocytes. 
Whereas, B-cell maturation takes place in the bone marrow, some CLPs get selected 
to migrate to the thymus. Bone marrow and thymus are referred to as primary or 
central lymphoid organs and provide a suitable environment for generation and 
development of lymphocytes. On the other hand, secondary or peripheral lymphoid 
organs, including lymph nodes, spleen, mucosal lymphoid tissues of the gut, the 
nasal respiratory tract, the urogenital tract and other mucosa, favor antigen 
encounter and initiation of immune responses by mature cells. Once CLPs arrive at 
the thymus, they commit to the T-cell linage. This commitment is most probably 
mediated by interactions with thymic stromal cells involving the notch-signaling 
pathway. 
 
The thymus consists of several lobules. These lobules are structured in two 
different regions (Figure 2). The cortex (outer region) contains epithelial cells and 
immature thymocytes surrounded by a subcapsular epithelium and a capsule. The 
medulla (central region) also contains epithelial cells, as well as macrophages, 
dendritic cells, Hassal’s corpuscle and mature thymocytes. Hence, thymocytes 
mature as they migrate deeper into the thymus. The outer cortical cell layer mostly 
contains proliferating immature lymphocytes, whereas immature cells already 
undergoing thymic selection are positioned further deep inside the cortex. Eventually, 
mature T-cells are found in the medulla. 
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 Figure 2 
The cellular organization of the human 
thymus. The Thymus is made up of lobules, 
which contain a cortical (outer) and a 
medullary (central) region. Cells present in 
the cortical region: immature thymocytes 
(dark blue), branched cortical epithelial cells 
(pale blue), scattered macrophages. Cells 
present in the medullary regions: mature 
thymocytes (dark blue), medullary epithelial 
cells (orange), macrophages and dendritic 
cells (yellow). (Janeway’s Immunobiology, 
seventh edition). 
 
Once committed to the T-cell lineage (as mentioned above), CLPs start 
expressing CD2 in humans, or Thy-1 in mice, which are cell surface molecules 
specific of T-lymphocytes. Four major subsets of immature T cells, distinguishable by 
their expression of CD4 and CD8 co-receptors, are found in the thymus. Cells 
expressing neither CD4 nor CD8 are called double negative (DN) and are the most 
immature, while cells expressing both co-receptors are named double positive (DP). 
Mature thymocytes express only one co-receptor, hence are defined as CD4+ or 
CD8+ single positive (SP) cells. 
DN cells account for about 5% of all thymocytes. They consist of 60% 
immature T cells that will express :  TCR restricted to MHC molecules. The 
remaining DN cells include mature :  T-cells, that do not express co-receptors, and 
NKT cells, bearing and :  T-cell receptor recognizing CD1 molecules as well as the 
NK1.1 receptor. :  T-cells are the first to appear in embryonic development and play 
a role in the gut mucosa and the epithelia of the reproductive tract. However, in the 
rest of this work we will focus on :  T-cells, which engage with MHC molecules and 
develop further into single positive T-cells. 
DN cells that lack the three markers defining mature T-cells, i.e. the T-cell receptor 
(TCR)/CD3 complex (see paragraph 1.2. TCR-complex signaling), CD4 and CD8 
receptors, can be further divided into four subsets named DN1 to DN4. The DN1 sub-
population is defined by expression of c-Kit (Stem Cell Factor receptor) and CD44 
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(an adhesion molecule) but not CD25 ( -chain of IL-2 receptor). At this stage, the 
genes encoding for the T-cell receptor are in germline configuration. In the DN2 sub-
population, both CD44 and CD25 are expressed and rearrangements of the T-cell 
receptor -chain locus begin (D  to J - rearrangement). Further V  to DJ - 
rearrangements and down-regulation of CD44 occur in DN3. Only cells, which exhibit 
productive -chain rearrangements lose CD25 expression and proceed to DN4 sub-
population. The assembly of a CD3:pre T-cell receptor complex (including a 
rearranged -chain coupled to a preT  subunit) enables signaling, which triggers 
proliferation and arrest of further -chain rearrangements. Shortly thereafter, both co-
receptors are expressed CD4 and CD8, thus giving rise to DP T-cells. 
 
Around 5x107 new cells are generated every day in the thymus of a healthy 
mouse. Nevertheless, only 2-4% of these cells exit the thymus as mature T-cells, 
while the remaining are eliminated during a process called thymic selection (Figure 
3). DP thymocytes, that represent the biggest cell population in the thymus, are 
selected at this stage by their ability to bind to self:peptide-MHC molecular 
complexes. T-cells, which do not bind die by apoptosis in a process called “death by 
neglect”. Cells that bind to self:peptide-MHC with too high affinity undergo “negative 
selection” and get eliminated as well at the DP and/or SP stage. This step prevents 
the production of cells with potential to create auto immune reactions. Hence, only 
cells whose TCR engages with self:peptide-MHC complexes with intermediate 
affinities escape deletion and are "positively selected" and continue their maturation 
process. 
 
Figure 3 
Thymocytes at different developmental stages 
are found in distinct parts of the thymus. 
Earliest precursor thymocytes enter the thymus 
near the cortico-medullary junction. 
Differentiation through DN stages (CD4- CD8-) 
until DP stage (CD4+ CD8+) takes place in the 
cortex. The medulla contains only mature 
single-positive T cells, which eventually leave the thymus. (Janeway’s Immunobiology, seventh 
edition) 
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It has been reported that upon maturation of T-cells (from DN- through DP- to 
SP-stage), expression of cell surface glycosyl-phosphatidylinositol–anchored 
protein CD24 (also known as heat stable antigen – HSA) decreases gradually (Kay 
et al., 1991). Conversely, the expression of the TCR/CD3-complex increases as T-
cell maturation progresses (Bonifacino et al., 1990). Hence, the expression levels of 
these markers are often used as indicators of possible deregulations in T-cell 
development. 
 
2.2. TCR-complex signaling 
 
This section shall introduce TCR-mediated signaling in mature T cells, giving an 
overview of the main proteins involved and their interactions. This will be followed by a 
detailed description of the structure and function of the adaptor protein SRC homology 2 
(SH2)-domain-containing leukocyte protein of 76 kDa (SLP76) and its role in a negative 
feedback loop regulating T cell activation. 
 
Dendritic cells (DC) are specialized or professional antigen presenting cells 
(APCs). These cells link innate and adaptive immunity and have the ability to engulf, 
proteolytically process and present antigens on their cell surface. DCs express major 
histocompatibility complex (MHC) on their surface, which carry processed peptide 
antigens for efficient presentation to T-cells (Figure 4). As previously mentioned T-
cells interact with APCs and scan their surface in search for non-self antigens. 
Activation occurs when a T-cell detects the presence of its specific antigen, loaded 
on the proper MHC, on the APC and triggers several intracellular signaling cascades. 
 
Figure 4 
Antigen-presenting cell (APC) engagement with a 
T cell. The APC’s histocompatibility molecule, 
loaded with an antigen peptide, binds to the T cell 
receptor and to co-receptor CD4 or CD8 (surface 
glycoproteins). These interactions trigger signaling 
events in the T cell. 
 
J.Kimball from: http://users.rcn.com/jkimball.ma.ultranet/BiologyPages 
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A TCR-complex is composed of a heterodimer of variable subunits (either  
or ), responsible for antigen recognition and several invariant accessory chains 
(the CD3 , CD3  and CD3  and the -chain/CD247) forming the signal-transducing 
module (Figure 5). Immediately after TCR stimulation, co-receptor bound 
lymphocyte-specific protein tyrosine kinase (LCK) phosphorylates Immunoreceptor 
Tyrosine-based Activation Motifs (ITAMs) in the intracellular domain of CD3 and -
chains. As a consequence, δ-chain-associated protein kinase of 70 kDa (ZAP70) is 
recruited and activated to further phosphorylate the scaffold proteins SLP76 
(Inoshima et al., 2012; Zhang et al., 1998) and Linker of activated T-cells (LAT) 
(Zhang et al., 1998). LAT is a transmembrane protein localized to cholesterol-rich 
membrane domains (lipid rafts). On the contrary, SLP76 is cytosolic in resting T-cells 
and constitutively bound to GRB2-related adaptor protein 2 (GRAP2, also known as 
GADS), an interaction dependent on the SH3-mediated binding of GADS to an Arg-
Ser-Thr-Lys motif of SLP76. (SH3-domains have a characteristic β-barrel structure, 
which normally binds to proline-rich amino acid sequences.) Upon TCR stimulation, 
GADS binds with its SH2-domain to phophorylated tyrosines of LAT, leading to 
translocation of the GADS-SLP76-complex to the membrane (Singer et al., 2004). 
(SH2-domains bind to phosphorylated tyrosine motifs). Assembly of LAT-GADS-
SLP76 provides a platform for the nucleation of a multimolecular complex that 
regulates initiation, amplification and duration of downstream signaling. Components 
of this include: the guanine-nucleotide exchange factor VAV1 and the adaptor non-
catalytic region of tyrosine kinase (NCK), involved in actin cytoskeleton regulation; 
the interleukin-2-inducible T-cell kinase (ITK) and phospholipase C (PLCγ), 
controlling intracellular calcium and diacylglycerol levels; the adaptor Growth factor-
receptor-bound protein 2 and the Son of Sevenless homologue (GRB2/SOS), 
activators of the Ras-ERK pathway; the integrin regulator Adhesion-and 
Degranulation-promoting Adaptor Protein (ADAP); the Hematopoietic Progenitor 
Kinase 1 (HPK1). Figure 6 presents an overview on the structure and functional 
domains on some of the signaling proteins mentioned above. 
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Figure 5 
Role of SLP76 in signaling through the T 
cell receptor. Ligation of the T-cell 
receptor (TCR) by MHC complexed with 
antigen results in sequential activation 
of LCK and ZAP70. ZAP70 
phosphorylates several downstream 
targets, including LAT and SLP76. SLP76 
is recruited to membrane-bound LAT 
through its constitutive interaction with 
GADS. Together, SLP76 and LAT 
nucleate a multimolecular signaling 
complex, which induces a host of downstream responses, including calcium flux, mitogen-activated 
protein kinase activation, integrin activation and cytoskeletal reorganization. (Koretzky et al., 2006) 
 
 
Figure 6 
A selection of signaling proteins found in T lymphocytes depicted to highlight their modular 
structures. SH2, SH3 and PH domains are in red, blue and green respectively. A Tec homology domain 
is in pink, and a transmembrane domain is in light green. Sites of tyrosine phosphorylation are 
indicated with Y and proline-rich sites are indicated Pro. Domains with enzymatic function are in 
yellow (Samelson, 2002). 
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2.3. SLP76  
SLP76 (Figure 7) has been intensively studied because of its critical role in both T-
cell development and mature T-cell function. This scaffold protein is expressed 
throughout the hematopoietic compartment, e.g. in platelets, neutrophils, mast cells, 
macrophages, natural killer (NK) cells, T-cells and developing B-cells. Initial 
investigations in SLP76-deficient Jurkat cells (known as J14-cells) revealed that 
SLP76 is a positive regulator of TCR signaling (Motto et al., 1996). Phosphorylation 
of ZAP70, LAT and ITK where normal in these cells whereas PLCγ1 phosphorylation 
and calcium flux where inhibited, indicating that SLP76 may link early signaling 
molecules to calcium release. Furthermore, up-regulation of CD69, a marker of T-cell 
activation, as well as of nuclear factor of activated T-cells (NFAT) and activator 
protein 1 (AP1) transcriptional activity were strikingly reduced (Yablonski et al., 
1998). Analysis of SLP76 knockout mice revealed the complete absence of 
peripheral T-cells resulting from an early block in thymic development (DN3 to DN4 
transition) (Clements et al., 1999). 
 
SLP76 can be divided into an N-terminal domain, a central proline-rich domain 
and a C-terminal SH2 domain. The N-terminal domain comprises 3 tyrosines (Y112, 
Y128 and Y145), which upon phosphorylation can serve as binding-sites for VAV, 
NCK and ITK, respectively. Mutation of these three residues demonstrated their role 
in promoting calcium flux, PLCγ1 phosphorylation and NFAT transcriptional activity 
(Fang et al., 1996; Yablonski et al., 2001). A fourth phosphorylatable tyrosine (Y173) 
has been recently identified, which is also required for TCR-induced phosphorylation 
of phospholipase C- 1 (Sela et al., 2011). Phosphorylation of all these sites is 
believed to be dependent on LCK- and/or ZAP70 protein kinases.  
The regulatory p85 subunit of phosphatidylinositol 3-kinase (PI3K), ITK and 
LCK also bind to the proline-rich domain of SLP76. GADS and PLCγ1 both bind to 
LAT and to the proline-rich domain of SLP76. Interestingly, mutation of the PLCγ1 
binding site on LAT not only abrogates binding to LAT, but also significantly 
decreases stability of SLP76-LAT-complex. These results highlight how multiple 
interactions within this molecular complex contribute cooperatively to the regulation 
of signal transduction.  
Recruitment and activation of CDC42 through VAV1 and NCK bound to SLP76 
activates both Wiskott-Aldrich syndrome protein (WASP) and p21-activated kinase 1 
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(PAK1), leading to actin polymerization (Bubeck Wardenburg et al., 1998). On the 
other hand ITK has been reported to play a role in T-cell activation, cytokine 
secretion and development of αβ T-cells as well as of non-conventional T-cells 
(August and Ragin, 2012). 
 
 
Figure 7 
Structural features of SLP76. SLP76 contains inducibly phosphorylated tyrosines in the amino (N) 
terminus, a central proline-rich domain and a carboxy (C)-terminal SH2 domain. These domains 
mediate binding to several other signal-cascade intermediates as shown (Koretzky et al., 2006). 
 
TCR engagement induces the SLP76- and ITK-dependent activation of 
PLCγ1, that catalyzes the formation of second messengers inositol-1,4,5-
triphosphate (InsP3) and diacylglycerol (DAG) from phosphatidylinositol 4,5-
bisphosphate (PIP2). InsP3 induces calcium release from the endoplasmatic-
reticulum, whereas DAG participates to the activation of protein kinase C (PKC) 
family members and Ras-MAP kinase pathway. 
 
 
2.4. The C-terminal SH2 domain of SLP76 binds to ADAP and HPK1 
 
ADAP is a positive regulator of LFA-1 integrin activation and signaling playing 
a key role in the formation of T-cell:APC conjugates (Wu et al., 2006). It has also 
been implicated in the regulation of T-cell survival, through the activation of NFkB 
signaling pathway downstream of TCR and CD28 and the induction of the pro-
survival factor Bcl-XL (Medeiros et al., 2007). T-cell proliferation and IL-2 production 
are impaired in ADAP deficient T-cells. However, ADAP effects on all the above-
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mentioned functions are Ag-dose dependent, being more profound only at very low 
antigen-doses (Mueller et al., 2007).  
Hematopoietic progenitor kinase 1 (HPK1), also known as MAP4K1, is a 
STE20-like protein serine/threonine kinase. In mammals, HPK1 is primarily 
expressed in hematopoietic cells and consists of an N-terminal kinase domain, a 
central proline-rich domain and a C-terminal citron homology domain (Figure 8). 
HPK1 activation and function depend on interaction with adapter proteins, as for 
instance with Grb2 family, Nck family, Crk family, SLP-76 family, and actin-binding 
adaptors like HPK1-interacting protein of 55 kDa (HIP-55). TCR-induced HPK1 
phosphorylation at Y381 in humans (Y379 in mouse) mediates binding to the SH2 
domain of SLP76 and therefore localization to the cell membrane. HPK1 has been 
implicated in a variety of signaling cascades and functions downstream of antigen-, 
growth factor- and cytokine-receptors, in apoptosis signaling and MAPK signaling. 
 
 
Figure 8 
HPK1 structure. HPK1 contains an N-terminal serine/threonine kinase domain, a C-terminal citron  
homology domain, four proline-rich motifs (PR1, PR2, PR3, and PR4), a caspase cleavage site  
(DDVD). Phosphorylation of tyrosine residue 381 induces HPK1 binding to SLP-76 SH2 domain. 
(Boomer and Tan, 2005). 
 
HPK1’s ability to activate c-Jun N-terminal kinases (JNK) suggests a role in 
regulation of NFAT gene transcription and IL-2 production. JNK activation is shown to 
mediate T-cell proliferation, Th1/Th2 differentiation and activation-induced cell death 
(AICD) (Boomer and Tan, 2005). 
Although HPK1 does not appear to interact directly with members of the 
MAPKs (Kiefer et al., 1996), overexpression of HPK1 in Jurkat cells has revealed a 
negative effect on Erk kinases and NFAT/AP1-dependent transcription (Liou et al., 
2000; Sauer et al., 2001), Conversely, other groups showed that HPK1 enhances 
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both AP-1 and IL-2 transcription (Hu et al., 1996; Ling et al., 1999; Ma et al., 2001). 
HPK1 also has been implicated in NF-κB activation, through IKK-α and -β activation, 
important for cell survival (Figure 9) (Hu et al., 1999). Studies in Jurkat cells have 
shown a constitutive binding of HIP-55 to HPK1. HIP-55-HPK1 complex negatively 
modulates NFAT-activity in cells stimulated by superantigen pulsed Raji B-cells. 
Interestingly, this effect can be reversed using kinase-dead HPK1 mutants, 
suggesting a kinase-dependent effect (Le Bras et al., 2004).  
 
Figure 9 
HPK1 function in TCR signaling. After TCR engagement, 
HPK1 is tyrosine phosphorylated and becomes 
activated. HPK1 may inhibit activation of ERK2, AP-1 
and transcription of IL-2 gene. On the contrary, HPK1 
may activate JNK, NF-kB, AP-1, and IL-2 depending on 
the cell type and stimuli used. HPK1 is believed to play a 
pro-apoptotic role by activating JNK and inhibiting NF-
kB activation after caspase cleavage in T-cells. Arrows 
indicate activation while bars indicate inhibition. HPK1 is labeled in pink, transcription factors are 
colored in yellow, signaling molecules are shown in light blue and MAPK kinases are colored in dark 
blue. P = phosphate group (green) (Koretzky et al., 2006).  
 
2.5. Immunological synapses and organization of signaling complexes 
 
Antigen recognition during the interaction of a T-cell with an APC induces the 
formation of a specialized cell-cell interface called immunological synapse. This 
intercellular junction is formed by recruitment and spatial reorganization of multiple 
proteins at the site of interaction. In T-cells, the recruited proteins assemble in 
signaling complexes or signalosomes, also known as “microclusters” (MCs). In some 
instances, the latter may organize in higher-level structures named supramolecular 
activation clusters (Dustin et al., 2010). MCs consist of receptors, kinases, 
phosphatases, other enzymes and adaptor proteins that trigger various signaling 
cascades. Presumably, multiple protein-protein interactions within these signaling 
modules cooperatively contribute to their assembly and stability, consequently, 
regulating the kinetics of activation of downstream signaling pathways. In particular, 
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the SLP76-GADS-LAT complex constitutes a critical nucleation site for signaling 
MCs, hence, it is predicted to play a major role in influencing their stability. In 
conclusion, MCs are rather short lived, tightly regulated signaling modules, which are 
formed upon TCR stimulation. MC formation and dynamics have been studied in 
surrogate synapses formed between T-cells and anti-CD3 antibody-coated glass 
slides. This artificial interaction serves as a well-established model to dissect the 
underlying molecular mechanisms of MC formation in vitro. Molecules that are 
included into MCs can be either tagged by fluorescent proteins or detected by 
immunofluorescence, thereby allowing to visualizing MCs by confocal microscopy. 
We used the latter approach to determine the role of SLP76-14-3-3 interaction in MC-
stability (Trautmann, 2005). 
 
 
2.6. Physical and functional interaction between HPK1 and SLP76 
 
In this section we will focus on the interaction between HPK1 and SLP76 and the role 
of these proteins in a recently discovered negative feedback loop regulating T-cell activation. 
Eventually, this will lead us to the introduction of our SLP76-S376A mouse mutant model, the 
presentation of our scientific questions and to an explanation of our methodical approaches 
in more detail.  
 
As previously discussed, TCR-engagement triggers the activation of tyrosine 
kinases, LCK and ZAP70, by tyrosine-phosphorylations. Previous studies have 
shown that HPK1 can be phosphorylated by ZAP70 at Y379, and bind to the SH2 
domain of SLP76 (Sauer et al., 2001), resulting in the recruitment of HPK1 to SLP76-
containing microclusters (Lasserre et al., 2011). Moreover, it has been shown that 
knockout of HPK1 in mice (Shui et al., 2007) or its knockdown by RNA interference in 
Jurkat cells (Di Bartolo et al., 2007) results in increased TCR proximal activation, 
underscoring the negative regulatory function of HPK1. For instance, HPK1 knockout 
mice show increased activation of T-cells upon TCR stimulation, represented by 
more persistent calcium flux, phosphorylation of PLCγ1 and Erk and increased 
cytokine production compared to wild-type mice (Shui et al., 2007). Interestingly, 
work conducted by the host laboratory has demonstrated that phosphorylation of 
residues S376 of SLP76 and T254 of GADS is controlled by HPK1 (Figure 10). 
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Moreover, these modifications are required for the association of 14-3-3 proteins 
(e.g. 14-3-3 ,  and  isoforms) to the SLP76-GADS complex (Di Bartolo et al., 2007; 
Lasserre et al., 2011). Mutation of these sites to alanine, abolishes their 
phosphorylation, therefore impairs 14-3-3 recruitment and increases stability of 
SLP76-containing microclusters as well as transcriptional activity of NFAT (Lasserre 
et al., 2011). Based on these data, a model has been proposed by which HPK1-
induced recruitment of 14-3-3 proteins leads to disassembly of SLP76-GADS 
complexes from LAT-containing microclusters, consequently to a down-regulation of 
SLP76-mediated signaling and T cell activation (Lasserre et al., 2011).  
 
Figure 10 
A schematic model of 
Slp76 regulation by 
HPK1 during T-cell 
signaling. Following TCR 
signaling, Lck is 
activated and 
phosphorylates Zap70, 
leading to 
phosphorylation and 
assembly of the Slp76 
complex. Tyrosine phosphorylation of HPK1 by Zap70 results in HPK1 translocation to GEMs and 
binding to the SH2 domain of Slp76. HPK1 subsequently phosphorylates Slp76 (and GADS, not 
depicted) and induce recruitment of 14-3-3 proteins. The recruitment of 14-3-3 to the Slp76 complex 
may result in down-regulation of TCR signaling, including PLC-γ1 and ERK phosphorylation as well as 
Ca2+ flux, leading to decreased IL2 transcription (Shui et al., 2007). 
 
Several observations indicate that HPK1 may play a role in some pathological 
conditions. For instance, HPK1 knockout mice showed increased susceptibility to 
inducible experimental autoimmune encephalomyelitis (EAE), a murine model of 
multiple sclerosis (Shui et al., 2007). Moreover, a reduced expression of HPK1 has 
been proposed to contribute to autoimmunity in patients suffering from systemic 
lupus erythematous (Zhang et al., 2011). HPK1 has also been implicated in the 
regulation of cytotoxic T-cells responses against cancer (Alzabin et al., 2010). 
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Indeed, HPK1 is activated in T-cells by the pro-inflammatory mediator prostaglandin 
E2 (PGE2), via a signaling pathway involving phosphorylation of HPK1 by the cAMP-
dependent protein kinase (PKA) (Sawasdikosol et al., 2007). Importantly, HPK1-
deficient T-cells were reported to be less sensitive to PGE2-mediated negative 
regulation of T-cell activation, showed increased levels of IL-2 production, increased 
cell proliferation as well as higher resistance to apoptosis compared to wild-type 
cells. Finally, HPK1 knockout mice were able to reject lung tumors that produce high 
amounts of PGE2 (Alzabin et al., 2010) although the molecular mechanism 
underlying this increased resistance to tumor development was not characterized. 
Interestingly, unpublished data obtained in the host laboratory have shown that 
treatment of T-cell lines with PGE2 does increase the interaction between 14-3-3 
proteins with GADS and SLP76. This supports a potential regulation of the HPK1-
dependent negative feedback loop, as described above, by PGE2. 
 
 
2.8. Introduction of SLP76-S376A knock-in mouse 
 
As previously mentioned, this S376 of SLP76 is phosphorylated by HPK1, 
providing a binding site for 14-3-3 proteins, which is crucial for the HPK1-mediated 
negative feedback loop on T-cell activation. 
A possible scenario, based on previous data obtained by the hosting 
laboratory, predicts that mutation of this site would increase the strength and/or 
duration of TCR-induced signaling. This would be explained by a reduced or absent 
negative feedback regulation, similarly to what have been observed in HPK1 
knockout mice. Such a modification in the signaling outcome may result in altered 
thymic selection and/or functional responses by mature T-cells. On the other hand, 
while HPK1 appears to also independently activate other signaling pathways (e.g. 
NFkB), mutation of the S376A is expected to specifically impair the HPK1-induced 
negative feedback loop acting on the SLP76- (and GADS-) dependent signaling axis 
(Figure 11A and 11B). Hence, the effects of SLP76-S376A mutation may only 
partially overlap with those of HPK1-deficiency.  
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Figure 11 
Model of regulation of stability of signaling microcluster and T-cell activation by HPK1. A) SLP76-
GADS complex are recruited to the phosphorylated transmembrane adaptor LAT to form signaling-
competent microclusters. When phosphorylated on Y381 (Y379 in mice), HPK1 is incorporated into 
microclusters by interacting with the SH2 domain of SLP76 and phosphorylates S376 of SLP76 and 
T262 of GADS. 14-3-3 proteins then bind to SLP76-GADS complexes through these phosphorylated 
residues, thus leading to dissociation of these complexes from phospho-LAT and terminating 
signaling. B) SLP76-S376A mutation prevents phosphorylation by HPK1, therefore impairing 
recruitment of 14-3-3 proteins and reducing negative regulation. (Lasserre et al., 2011) 
A 
B 
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To test these hypotheses, the host laboratory has recently generated a knock-
in mutant mouse bearing a serine to alanine point mutation on the SLP76 protein at 
S376 (SLP76-S376A mouse). This model will allow studying the impact of this 
specific mutation on T-cells’ development and function. Furthermore, it will enable us 
to address similar questions in other hematopoietic lineages expressing SLP76. This 
model will also be helpful to address the effect of the SLP76-S376A mutation in a 
pathological setting, such as cytotoxic T-cell responses against PGE2-producing 
solid tumors. 
 
2.9. Aim of this work 
 
The aim of this master’s thesis was to contribute to the initial characterization 
of the SLP76-S376A mutant mouse model. In particular, my work focused on two 
points:  
1. The analysis of T-cell activation and development in SLP76-S376A mice 
2. The setup of an experimental cancer model to test the potential effects of the 
SLP76-S376A mutation on cytotoxic T cell responses in vivo.  
 
For the developmental studies, I compared the proportions of different thymic 
subpopulations between wild type and mutant mice, by monitoring the expression of 
several markers including CD3, CD4, CD8, CD24, CD25 and CD44 in developing 
thymocytes.  
In order to evaluate T-cell activation, I first used flow cytometry and western blot to 
analyze the phosphorylation of several proteins involved in T cell signaling pathways 
upon TCR stimulation. These included Erk kinases (pT202/pY204), SLP76 (Y128) 
and upstream regulators of the NFkB pathway such as PKC  and IKKβ.  
In addition to that, I worked on a method to visualize and quantify microcluster-
formation in mouse T-cells, using confocal microscopy. This approach was previously 
established in the host laboratory to demonstrate the effects of SLP76 and/or GADS 
mutations on the stability of SLP76- and LAT-containing signaling microclusters, in 
both Jurkat T-cells and primary human T lymphocytes (Lasserre et al., 2011). 
I also analyzed the functional response of wild type and mutant T-cells ex vivo 
by measuring the production of cytokines and the proliferative response of T cells 
upon TCR and CD28 stimulation. Indeed, mutant T-cells where expected to be 
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hyper-responsive to TCR stimulation, hence, to proliferate more than wild type T-cells 
and/or produce more cytokines. In this respect, we chose to measure the production 
of IL-2, a well-known T-cell growth and differentiation factor produced by both CD4 
and CD8 T-cells upon stimulation (Kish et al., 2005; Smith, 1988), and INF-γ, which 
is important for cell-mediated immune responses (e.g. anti-viral and anti-tumor 
immunity). Another reason for focusing on detection of INF-γ was because of its 
reference to CD8+ T-cell activation (Ikeda et al., 2002).  
Finally, I started to generate new tools for the analysis of an anti-tumor 
response in SLP76-S376A and control mice. For this purpose, I used a Lewis lung 
carcinoma (LLC) cell line, which has previously shown to be efficiently rejected in 
vivo and killed in vitro by HPK1-deficient T-cells (Alzabin et al., 2010). My goal was to 
modify LLC cells by transfecting them with a reporter luciferase gene. This would 
allow us to easily visualize and quantify tumor growth and rejection by measuring 
luciferase-dependent bioluminescence in animals in vivo and/or ex vivo. 
 
In conclusion, the experimental approaches outlined above led to the following 
results: 
1. TCR-induced signaling was increased in SLP76-S376A compared to normal T-
cells, as demonstrated by increased phosphorylation of ERK1/2 kinases. 
2. Both CD4+ and CD8+ mutants T-cells exhibited increased proliferation and CD8+ 
mutant T-cells showed higher INF-γ production upon co-stimulation with agonist anti-
CD3 and -CD28 antibodies.  
3. No significant differences were observed in T-cell development between wild type 
and mutant mice. 
4. Initial experiments demonstrated that a bioluminescent reporter LLC cell-line can 
be generated and that tumor formation can be measured both in vivo and ex vivo 
upon injection of these cells in mice.  
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3. Materials and Methods 
 
3.1. Cell culture 
 
3.1.1. B16-F10 mouse melanoma cell line 
 
This cell line was obtained from Marc Daëron’s lab laboratory (Institut Pasteur, 
Paris – France). B16-F10 cells were derived from B16 melanomas (malignant tumor 
of melanocytes) after selection for their ability to form metastases in the lung of 
C57BL/6J mice (Nicolson et al., 1978). B16-F10 cells grow in vitro as adherent cells 
with a mixed spindle shaped and epithelial-like morphology. They were cultured in 
Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 10% FCS, 2mM 
Penicilin and 2mM Streptomycin and were split 3 times a week at a 1:6-ratio. In order 
to find a suitable cell line for a tumor rejection experiment this cell line was tested for 
Prostaglandin E2 (PGE2) expression, however, PGE2 could not be detected in cell 
culture supernatant.  
 
 
3.1.2. Lewis lung carcinoma 
 
“Lewis lung carcinoma” (LLC or 3LL) was a gift of Dr. Karim Benihoud (Institut 
de Cancerologie Gustave Roussy, Villejuif - France). This cell line was derived from 
spontaneous lung tumors of the C57BL/6 mouse strain (Bertram and Janik, 1980) 
and was reported to be tumorigenic in C57BL/6 mice forming lung tumors. LLC cells 
express high levels of PGE2, which was shown to be important for tumor engraftment 
in the lungs (Young and Knies, 1984) . These cells were cultured in DMEM 
supplemented with10% FCS, 2mM Penicillin and 2mM Streptomycin. The estimated 
doubling time for LLC cells is approximately 21 hours. LLC cells grow partly as 
monolayer and partly in suspension and were routinely split 3 times a week at a ratio 
of 1:5. 
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3.1.3. T8.1 cell line 
 
T8.1 is a murine T-cell hybridoma expressing human CD4 receptor and a 
chimeric mouse (C ,C ) – human (V ,V ) – T-cell receptor (TCR) (Hogquist et al., 
1994). It does not to express any detectable levels of PGE2, therefore, it served as a 
negative control for PGE2 detection assays. The medium used for keeping T8.1 cells 
in culture was DMEM supplemented with 10% FCS, 2mM Penicillin and 2mM 
Streptomycin, 400nM methotrexate, 1mg/ml G418 and 50 M 2-mercapto-ethanol. 
 
 
3.2. LLC transfection with pGL4.50 luc2/CMV/Hygro  Vector 
 
3.2.1. pGL4.50 luc2/CMV/Hygro  Vector 
 
 Lewis lung carcinoma cells have been transfected with a luciferase reporter 
vector (pGL4.50 luc2/CMV/Hygro  vector) (Figure 12). The goal was to set up a 
technique for “in vivo tumor detection”, using a bioluminescent luciferase reporter cell 
line. The plasmid used is 6600bp of size and carries a CMV (cytomegalovirus) 
immediate early enhancer/promoter for high translational expression. It contains a 
hygromycin B -resistance gene for mammalian cell 
selection as well as an ampicillin resistance gene 
for bacterial selection (vector amplification). 
Furthermore, this vector encodes the luciferase 
gene “luc2” derived from the common eastern firefly 
(Photinus pyralis). A SV40 late poly (A) signal 
sequence is positioned downstream of luc2 for 
efficient transcription termination. This vector was 
obtained from “Promega” - Catalog#E1310.     Figure 12 
        pGL4.50[lac2/CMV/Hygro] Vector 
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3.2.2. Transfection of LLC cells using FuGENE  6 Transfection Reagent 
 
One day before transfection, LLC cells were seeded in a six well plate at 3 
different cell concentrations: 0.5 x106, 1 x106 or 2 x106 per well. The day of the 
experiment the culture medium was replaced with serum free medium (SFM - 
DMEM); the plasmid DNA complex was mixed with the FuGENE 6 transfection 
reagent (Roche Applied Science). 97µl of SFM were dispensed into a 1.5 ml 
Eppendorf tube. Then 3µl of FuGENE 6 reagent were added directly into the medium 
followed by addition of 1µg of the pGL4.50 luc2/CMV/Hygro  vector. For efficient 
stabilisation of the FuGENE – plasmid DNA complex, reagents were incubated for 15 
minutes at room temperature. After incubation, 100µl of FuGENE – plasmid DNA 
complex were added to LLC cells (at 60% - 80% confluency) in a 6-well plate, by 
pipetting the solution in a dropwise manner across the well. 
After further 6 hours incubation at 37°C, culture medium was exchanged with 
complete medium supplemented with FCS. Three days later transfected cells were 
selected by adding hygromycin to the culture medium at two concentrations: 
0.8mg/ml and 1mg/ml. Cells selected with 0.8mg/ml are referred to as LLC – 
LUC2/0.8, whereas those selected with 0.8mg/ml are referred to as LLC – LUC2/1. 
Significant growth of LLC – LUC2/0.8 cells was observed after 3 weeks of selection 
in hygromycin-containing medium, whereas recovery of LLC – LUC2/1 required 4 
weeks. During the selection period dead cells were occasionally removed, but cells 
were never split. 
 
 
 
3.3. Prostaglandin E2 (PGE2) detection 
 
For detection of PGE2 the DetectX  “Prostaglandin E2 high sensitivity 
immunoassay kit” (Arbor Assays LLC, Michigan, USA) has been used. The following 
cell lines were examined for PGE2 production: Lewis lung carcinoma (LLC), LLC – 
LUC2/1, LLC – LUC2/0.8, B16-F10 mouse melanoma,T-cell hybridoma T8.1 (used 
as negative control). 
 
26 
 
3.3.1 Procedure and assay principle 
 
This kit allows the detection of PGE2 present in the samples by competitive 
immunoassay. Cells were counted and equally distributed into a 96-well plate in 
complete culture medium. After two days, 200 l of supernatant was taken as sample 
for each cell line. Samples were diluted in a 1:5 and 1:10 ratio before starting the 
assay. 100 l of samples were distributed into a 96 well plate coated with goat anti-
mouse IgG, provided with the kit. Thereafter, the following reagents have been added 
to each well: 100 l of assay buffer, 25 l “DetectX  Prostaglandin E2 Conjugate” 
(PGE2 conjugated to horseradish peroxidase: PGE2-HRP), 25 l “DetectX  
Prostaglandin E2 high sensitivity antibody”. The binding reaction was initiated by 
adding the mouse monoclonal high sensitivity antibody against PGE2. Hence, PGE2 
contained in samples or PGE2-HRP could bind to the anti-PGE2 antibody and were 
captured by anti-mouse IgG antibody, previously immobilized to the bottom of the 
wells. After 16 hours incubation at 4°C, each well is washed 4 times with 300 l 
washing buffer, then dried and 100 l of TMB substrate were added to each well. 
After 30 minutes incubation at room temperature, the peroxidase reaction was 
stopped and measured by reading the optical density at 450nm. PGE2 concentrations 
of samples were determined using a standard curve prepared with the provided 
PGE2 standard. 
 
3.4. Mice 
 
C57BL/6 mice were purchased from Elevage Janvier (Le Genest Saint Isle, 
France). The SLP76-S376A knock-in mice were generated by the “Plate forme 
d’Exploration Fonctionnelle du Système Immunitaire de la Souris” (Marseille, 
France). These mice were generated on a mixed 129 x C57BL/6 background, then 
backcrossed on C57BL/6 background for more than 8 generations. All animals were 
healthy reproduced with Mendelian ratios and had a normal life span. Concerning 
lymph node and spleen tissue of the mutant, there were no remarkable changes in 
cell numbers and no further anomalies noticed. 
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3.5. CD4+ or CD8+ T-cell purification 
 
Untouched CD4+ or CD8+ T-cells from mice were isolated by negative 
selection (or depletion), using commercially available CD4+ (or CD8+) T-cell isolation 
kits respectively (Miltenyi Biotec). Spleen and lymph nodes from mice were 
dissociated and cells pooled to maximize T-cell recovery. Cells were resuspended in 
MACS-buffer (PBS, 0,5%BSA, 2mM EDTA - 40 l per 107 total cells) before 
incubation for 20 minutes at 4°C with a “biotin-antibody cocktail” (10 l per 107 total 
cells). This biotin-antibody cocktail contains antibodies directed against the following 
surface markers: CD8 (or CD4), CD11b, CD11c, CD19, CD45R, CD49b, CD105, 
MHC class II and Ter119. 
These antibodies allowed to mark and remove all unwanted cell types from the 
sample, e.g.: CD8+ (or CD4+) T-cells, B-cells, dendritic cells, NK-cells, 
macrophages, granulocytes, endothelial cells and erythroid cells. 
After incubation with biotin-antibody cocktail, cells were washed by adding 
MACS-buffer (30 l per 107) before incubating 20 minutes at 4°C with “anti-biotin 
micro beads” (20 l per 107). These magnetic micro beads, conjugated to monoclonal 
anti-biotin antibodies, allowed capturing all the cell types previously labeled with 
biotin-conjugated antibodies. Samples were applied to a magnetic column of an 
autoMACS Pro Separator and sorted using the “DepleteS” (S = sensitive) program. 
Unlabeled CD4+ (or CD8+) T-cells were collected in the flow-through (first fraction). 
On the other hand, all cell types bound to the micro-beads were retained by the 
magnetic column during the separation procedure and collected in the second 
fraction.  
 
3.6. Activation-induced phosphorylation experiments, using western blot 
 
3.6.1. T-cell activation using soluble biotin labeled anti mouse CD3  and CD28 
antibodies 
 
Different techniques were employed for in vitro activation of T-cells. Activation 
using cross linking of biotin-labeled anti-mouse CD3  and biotin CD28 antibodies 
was used for detecting changes in phosphorylation of intracellular signaling proteins. 
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We chose fluorescence activated cell sorting (FACS) and westernblot as read out for 
these experiments. 
Once CD4+ (or CD8+) T-cells were purified and counted, they were 
resuspended in OPTI-MEM – medium and kept on ice. Cell-concentration varied 
between 15x106/ml and 30x106/ml. 100 l were taken out (corresponding to 
approximately 1.5 to 3x106 cells) before activation and kept on ice until the end of the 
experiment (non-activated negative control). Opti-MEM antibody mix (Opti-MEMAb-
mix) was prepared at a concentration of 10 g/ml for biotin labeled anti-mouse CD3  
and anti-mouse CD28 antibodies. 
 
3.6.2. Activation for western blot 
 
Streptavidin molecules, which display a very high affinity for biotin, where used 
to cross-link biotinylated molecules (e.g.: anti-CD3 and anti-CD28), thereby clustering 
receptors at the cell surface and triggering signal transduction. This approach serves 
as a well-established method to induce activation-dependent T-cell signaling 
cascades. Briefly, cells were centrifuged at 930xg for 8 minutes at 4°C and 
resuspendedinOpti-MEMAb-mix. Following 30 minutes of incubation on ice, cells 
were washed twice in Opti-MEM at +4°C. A water bath as well as an Opti-MEM 
streptavidin solution (Opti-MEM-StrAv) at 5 g/ml final concentration, were 
equilibrated at +37°C. To start the activation, cells were kept in one single tube and 
Opti-MEM-StrAv was added after centrifuging and aspirating the supernatant. 
Immediately after resuspension in Opti-MEM-StrAv cells were put into the 37°C water 
bath. For each time point, a 100 l aliquot was taken out and transferred into 
previously prepared Eppendorf tubes containing ice-cold “stopping buffer”. Stopping 
buffer contains phosphatase inhibitors to prevent removal of activation induced 
phosphorylation. Immediate centrifugation for 8 minutes at +4°C was followed by 
addition of 30 l of cell-lysis buffer to the cell pellet. After 10 minutes incubation on 
ice, tubes were centrifuged at 13000g for further 10 minutes before transferring 
supernatant into new Eppendorf tubes. This step served for the elimination of 
detergent-insoluble material, including nuclei and free DNA, which might interfere 
with western blotting. At this point, proteins were stored overnight at -80°C. 
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3.6.3. Protein quantification 
 
After cell lysis protein concentration in each sample was quantified in order to 
load equal protein amounts in each gel lane. DC™ Protein Assay kit (Bio-rad) was 
used for this purpose, according to the manufacturer instructions. Quantification was 
performed in a 96-well plate using a BSA standard curve. As mentioned in the 
handbook, 20 l of reagent S was added to 1ml of reagent A, therefore creating 
reagent A’. 5 l of BSA standard or 4 l of total protein samples were added to a 96-
well plate, followed by addition of 25 l of regent A’ and thereafter 200 l of reagent B 
(to each well). After incubating samples with reagent mix for 15 minutes at room 
temperature, optical density at 690nm was determined. Protein concentration was 
calculated from sample’s optical density by comparison with the BSA standard curve. 
Usually 4 g of total protein were loaded in each gel lane. 
 
3.6.4. Polyacrylamide gel electrophoresis 
 
An appropriate volume of protein lysates was diluted to 22.75 l and mixed with 
8.75 l 4x NuPAGE LDS sample buffer and 3.5 l reducing agent, then heated at 
+70°C for 10 minutes for protein denaturation. Samples were then cooled at room 
temperature and loaded on CriterionTM XT precast gels (4-12% Bis-Tris, 18-well 
comb, 1.0mm thickness). 10 l of protein ladder (consisting of 4.5 l Precision plus 
proteinTM all blue standards (Bio-Rad), 7.5 l 4x NuPAGE LDS sample buffer and 
18 l distilled H2O) was used to estimate the relative protein mobility. Finally, the gel 
was placed in the appropriate thank with 500ml MOPS running buffer and proteins 
were fractionated by applying an electric field (170 Volt) for approximately one hour  
 
 
3.6.5. Protein transfer to membrane (blotting) 
Following electrophoresis, proteins were transferred from the gel to a 
nitrocellulose membrane (LI-COR Bioscience, USA). The set up for this transfer was 
done as shown below in Figure 13.  
 
 
30 
 
Figure 13 
Protein blotting 
apparatus. From top 
to bottom: Anode 
(red), sponges (grey), 
Whatman 3MM 
paper (light grey), membrane (light blue), polyacrylamide gel (green), Cathode (black). When current 
is applied proteins migrate to the anode, therefore transfer from acrylamide gel to membrane 
occurs. 
 
Transfer buffer (25mM Tris, 192mM glycine, 20% ethanol), an ice-cold cooling 
pack and a stirring magnet were added to the Criterion transfer tank containing the 
transfer assembly as shown above, before applying an electric field (100V) for 90 
minutes. 
After protein transfer, membrane was treated with Ponceau S (1:64-dilution) 
for approximately 5 minutes for total protein staining. A picture of the membrane was 
taken using a common copy machine. Subsequently, membrane was destained by 
incubation in Tris-buffered saline (TBS). 
Membrane was treated with Blocking Buffer for Fluorescent Western Blotting 
(Rockland) for one hour at room temperature. This step is necessary to prevent 
unspecific antibody binding to the membrane. Blocking buffer was then removed and 
primary antibody solution (1:1 mix of TBS-0.1% Tween20 (TBST) and blocking 
buffer, containing the appropriate antibody) was added for 2 hours at room 
temperature or over night at +4°C. After washing the membrane three times with 
TBST for 5 minutes, the appropriate secondary antibody (coupled to either AF680 or 
DyLight800 fluorochromes) was diluted in 1:1 TBST-blocking buffer and added for 30 
minutes at room temperature. After washing the membrane as explained above, the 
membrane was stored in TBS until fluorescence detection and quantification using an 
Odyssey near-infrared scanner (LI-COR Biosciences USA). The phosphorylation of 
following proteins was monitored: Lat (Y191), Erk1/2 (pT202+pY204), SLP76 (Y128), 
PLCγ1 (Y783), IKK-α/β (S181/180), PKCθ (T538). 
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3.7. Flow cytometry experiments 
 
Flow cytometry (FCM) experiments were performed using either a BD 
FACSCalibur flow cytometer or Miltenyi biotech MACSQuantAnalyzer. 
FCM is a robust technique widely applied in immunology research. Among other 
applications, it allows to identify (and sort) different cell populations with distinct 
features or markers. These “markers” are usually recognized by spec ific antibodies, 
which are labeled with distinct fluorochromes, thus allowing the identification of each 
population in the flow cytometer. 
As described in the introduction stimulation of T-cells triggers a plethora of 
intracellular signaling pathways. We were interested in early T-cell receptor (TCR) 
signaling intiated by LCK (lymphocyte-specific protein tyrosine kinase) mediated 
phosphorylation of ITAM’s (immunoreceptor tyrosine-based activation motif) in the 
CD3-chains and eventually down to SLP76 (SH2 domain containing leukocyte 
protein of 76kDa), LAT (Linker of Activated T cells), PLCγ1 (Phospholipase C γ1) and 
Erk (extracellular-signal-regulated kinase or classical MAP kinase) phosphorylation. 
Moreover, we were interested in downstream activation events, such as cytokine 
production and cell-proliferation. Finally, we also investigated changes in thymic T-
cell development using specific markers to follow the maturation-dependent 
generation of the major thymocyte subsets. 
All FCM data analyses were performed using Flow Jo (Tree Star Inc, USA) 
software. 
 
 
3.7.1. Activation-induced phosphorylation experiments, using flow cytometry 
 
3.7.1.1. T-cell activation for phosphorylation experiments using FCM 
 
For each kinetics time point, cells were activated in a separate eppendorf tube 
containing 100 l of cell suspension (corresponding to approximately 1.5 to 3x106 
cells/tube) Incubation with Opti-MEMAb-mix and activation with Opti-MEM-StrAv 
were done as mentioned above always using 100 l per tube. Activation was stopped 
by immediate fixation of cells by adding 100 l of 8%PFA (leading to a final 
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concentration of 4% PFA). After incubating 10 minutes at room temperature, cells 
were washed twice with 500 l PBS to remove PFA and resuspended in FCM buffer.  
 
 
3.7.1.2. Detection of phosphorylation 
 
After stopping cell activation by PFA fixation, 2 washes in 500 l PBS were 
necessary to remove PFA. Following the first wash, cells were transferred to 5ml 
tubes. After the second wash PBS was aspirated and 500 l ice-cold methanol was 
added drop by drop while vortexing. Methanol treatment allows permeabilization of 
cells and was performed for 10 minutes at +4°C. Cells were then immediately 
subjected to the staining procedure or stored at –20°C and treated later on. Following 
methanol incubation, cells were centrifuged at 2000rpm for 8 minutes, then methanol 
was aspirated and cells resuspended in FCM buffer (PBS, 2.5%FCS, 0.02% sodium 
azide). Subsequently, staining of surface and intracelluluar proteins were performed 
at the same time (CD4-FITC, CD8-APC, rabbit anti-pErk/anti-rabbit-AF647, pSlp76-
AF647). Cells were transferred into a 96-well plate, resuspended in previously 
prepared antibody mix and incubated for 45 minutes at +4°C. After incubation two 
washes with FCM buffer were performed, to eliminate antibody excess before 
resuspending cells in 200 l FCM buffer. Samples were immediately analysed by 
using a MACSQuantAnalyzer (Miltenyi Biotec). 
 
 
3.7.2. Cytokine production assay 
 
3.7.2.1. Pre-coating 96-well plates for cytokine production assay 
 
50 l of an anti-mouse CD3  solution (10 g/ml in PBS) were distributed into a 
96-well plate. For negative controls 50 l PBS was added into the wells. The plate 
was then sealed and incubated over-night at +4°C. The following day, antibodies had 
adhered to the plate’s surface; unbound antibodies were removed by washing once 
with PBS.  
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3.7.2.2. Detection of cytokine production 
 
For this assay, we used 96-well plates pre-coated with stimulatory antibodies 
as mentioned above. Before starting the experiment 75 l of a 20 g/ml “anti mouse 
CD28 antibody solution” (in complete culture medium) or 75 l of “Phorbol 12-
myristate 13-acetate (PMA) – plus calcium ionophore (A23187) solution” was added 
to sample- or control-wells respectively. Incubation with complete culture medium for 
45 minutes at 37°C was necessary to block unspecific binding sites on plastic wells. 
The PMA – calcium ionophore mixture triggers strong T-cell activation, hence 
cytokine production, and is therefore typically used as a positive control.  
Total LN cells were resuspended in complete culture medium at a cell concentration 
of 6.6x106/ml. By adding 75 l of LN cells, the final concentration of anti mouse CD28 
antibody was reduced to 10 g/ml. Final concentrations of and calcium ionophore 
were 50ng/ml and 0,5 g/ml respectively. 
After 2 hours of incubation at 37°C, brefeldin A (BFA) was added to each well to a 
final concentration of 1 g/ml. BFA is reported to induce retrograde protein transport 
from the Golgi apparatus to the endoplastmatic reticulum (ER). Thus leading to the 
accumulation of cytokines in intracellular compartments and preventing their 
secretion. This facilitates detection of cytokine expression by FCM. Further 
incubation for 4 hours at 37°C, was necessary to accumulate detectable amounts of 
the cytokines of interest. 
 
Cells were then removed from the plate by pipetting thoroughly up and down 
and washed twice in FCM buffer (PBS, 2.5%FCS, 0.02% sodium azide), spinning 
down 5 minutes at 1500rpm. Cells were resuspended and incubated 30 minutes at 
+4°C in the antibody solution. CD4-FITC and CD8-APC conjugated antibodies were 
used for the surface staining of T-cell subsets. Subsequently, cells were washed 
twice in FCM buffer then incubated in 100 l fixation/permeabilization buffer (BD 
Biosciences) for 20 minutes at +4°C. This incubation was followed by two washes 
with Perm/Wash buffer (BD Biosciences). From this moment onwards, washes were 
performed with Perm/Wash buffer, diluted 1:10 with distilled water. IFN-γ-PE and IL-
2-PE antibodies diluted Perm/Wash buffer were used for intracellular staining. Cells 
were incubated in antibody solution for 15 minutes, at room temperature. After 
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incubation, cells were washed twice in Perm/Wash buffer and finally resuspended in 
FCM buffer. All the washing steps included centrifugation for 5 minutes at 930xg. 
Experiment was immediately read on a MACSQuantAnalyzer (Miltenyi biotech). 
 
 
3.7.3. Proliferation assay 
 
3.7.3.1. Pre-coating 96-well plates for proliferation assay 
 
Pre-coating of 96-well plates with stimulatory antibodies for proliferation assay 
was performed in a similar way as mentioned above for the cytokine production 
assay, with slight modifications. Antibody mix solution contained anti-mouse CD3  
and CD28 antibodies in PBS, at a concentration of 5 g/ml and 10 g/ml, respectively. 
The procedure was continued as mentioned above. Hence, both anti-mouse CD3  
and anti-mouse CD28 antibodies were adsorbed on to the plate’s surface, whereas 
for the cytokine production assay the anti-CD28 antibody was added in a subsequent 
step in solution. Adding soluble anti mouse CD28 resulted in improved detection of 
cytokine production. 
 
 
3.7.3.2. Mouse T-cell proliferation assay 
 
This assay is based on the loss of a dye named carboxyfluorescein 
succinimidyl ester (CFSE) by stained cells, during their proliferation. CFSE is a viable 
fluorescent dye with an emission maximum at 517nm (detectable in the FITC 
channel) that covalently bind to cellular proteins. At each cell division, cells lose 
CFSE signal because of the dilution of labeled proteins between daughter cells. 
Hence, measuring dye dilution by analyzing cells with a flow cytometer, allows 
counting of the number of divisions performed by each cell in the population. 
The assay was performed by stimulating cells in 96-well plates, which were 
pre-coated with antibodies as mentioned above. Before starting the assay, 100 l 
complete culture medium was distributed into relevant wells and incubated for 45 
minutes to block unspecific binding of cells to the plastic surface of wells. Meanwhile 
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a 10 M CFSE solution in PBS was prepared for staining lymph node cells. Lymph 
nodes cells were dissociated counted and resuspended in Opti-MEM medium at a 
cell concentration of 5x106. CFSE solution was mixed with cells in a 1:1 volume ratio 
and incubated for 15 minutes at +37°C. Subsequently, two washing steps were 
performed with 5ml complete culture medium. Afterwards, cells were distributed into 
the pre-coated and blocked 96-well plate (100 l per well corresponding to 500.000 
cells) and incubated at 37°C. 
 
After 72 hours, the plate was centrifuged at 1500rpm for 8 minutes and 
supernatant was removed. 50 l PBS were added to each well and thoroughly 
pipetted up and down to detach cells. Subsequently, cells were washed once in 
100 l PBS, resuspended in 50 l antibody mix containing CD4-PE and CD8-APC in 
PBS, then incubated for 45 minutes at +4°C. Finally, cells were washed twice, 
resuspended in 200 l FCM buffer and immediately analyzed using a 
MACSQuantAnalyzer (Miltenyi biotech). 
 
3.7.4. Thymic T-cell development 
 
T-cell development in the thymus is essential for central tolerance. Aberrant 
regulations during this process can create an imbalance, leading to enhanced 
autoimmune reactions. We analyzed potential alteration in thymocyte development in 
SLP76-S376A knock-in mice by assessing the expression of common maturation 
markers, including the co-receptors CD4 and CD8, the TCR-associated CD3 chain 
and other membrane proteins such as CD24 (or HSA – heat stable antigen), CD25 
and CD44. 
Thymi were dissected and dissociated as described for spleen and lymph 
nodes. Cells were counted and resuspended in complete DMEM culture medium at a 
cell concentration of 15 x106/ml and 200 l/well were distributed on a 96-wellplate 
(corresponding to 3 x106 cells) for antibody surface staining. Cells were centrifuged 
for 8 minutes at 930xg, washed twice with FCM buffer before adding the antibody 
mix. Cells were then incubated 45 minutes at +4°C, washed twice in FCM buffer and 
finally resuspended in 200 l FCM buffer. Experiment was immediately read using a 
MACSQuant Analyzer (Miltenyi biotech). 
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3.8. Immunofluorescence and confocal microscopy 
 
3.8.1. T-cell activation using anti-mouse CD3  and CD28 antibody-coated 
coverslips for immunofluorescence 
 
The aim of these experiments was to visualize the activation-dependent 
assembly of signaling protein complexes (microcluster) in T-cells, using confocal 
microscopy. In order to achieve efficient coating with the stimulating antibodies, glass 
coverslips were first incubated with poly-L-lysine, which provides binding sites for the 
activating antibodies. Subsequently, coverslips were incubated with anti-mouse CD3 
and CD28 antibodies. Cells were activated by dropping them on the cover slips and 
activation was stopped by fixation using 4% PFA. After washing carefully with PBS 
cells were permeabilzed with saponin, stained with anti phospho-Lat (Y191) and anti- 
phospho-SLP76 (Y128) antibodies. 
 
3.8.1.1. Preparation of antibody coated coverslips 
 
Coverslips were cleaned by soaking them in 50ml of a 70% ethanol, 1N HCl-
solution. After incubation for 10 minutes, two washes with distilled water and one 
wash with 70% ethanol were performed. Subsequently, coverslips were dried before 
distributing them into a 24-well plate (one coverslip per well). 2ml of a 1/10 poly-
lysine dilution was added to each well, followed by 30 minutes incubation at room 
temperature. Coverslips were again completely dried on Whatmann paper. 
Incubations with the ethanol-HCl solution as well as with poly-L-lysine were 
performed on a shaker. 
 
3.8.1.2. Coating with anti mouse CD3  and anti mouse CD28 antibodies 
 
Poly–L–lysine-coated coverslips were treated further with anti-mouse CD3  
and CD28 antibodies in the following manner. 
Two square pieces of Whatmann 3MM paper (big enough to fit the desired number of 
coverslips) were made wet with water and put on a flat surface (e.g.: small plastic 
tray). An equally sized piece of parafilm strip was placed on top of wet paper sheets. 
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The parafilm serves as a surface for applying 80 l drops of antibody mix solution 
(antibody mix solution: 10 g/ml for hamster anti mouse CD3  [clone 145-2C11] and 
10 g/ml for hamster anti-mouse CD28 [clone 37.51]). One poly–L–lysine coated 
coverslip was placed on top of each drop. Plastic tray was sealed and incubated over 
night at +4°C. The wet Whatmann 3MM paper provides sufficient humidity during the 
incubation, since it is crucial not to let completely dry antibody-coated coverslips. 
 
3.8.2. T-cell activation on coverslips pre-coated with anti-mouse CD3  and anti-
mouse CD28  
 
After over night incubation at +4°C, coverslips were pre-coated with activating 
antibodies. A 24-well plate was filled with PBS (1ml per well) before transferring each 
coverslip into one well, antibody coated side facing up. PBS was aspirated and 
coverslips were washed again with 1ml pre-warmed PBS, to get rid of antibody 
excess. Subsequently, PBS was removed and 200 l of RPMI medium containing 
10%FCS was added to each well. The 24-well plate was incubated at +37°C for 45 
minutes. This was performed to block unspecific antibody binding sites on the 
coverslips. 
For activation on coverslips we used purified CD4+ or CD8+ T-cells. After 
purification, cells were resuspended in serum-free RPMI medium at a cell 
concentration of 5x106/ml. An aliquot was kept as negative control, whereas the rest 
of the sample was resuspended in RPMI supplemented with 10%FCS. We used 
coverslips, pre-coated with poly-L-lysine as a negative control, since, in the abscence 
of stimulating antibodies cells were not activated and microcluster formation was 
hardly detectable. For these negative control samples, no serum is added to medium 
in order to favour the attachment of cells to coverslips. Activation was performed by 
putting the 24-well plate containing coverslips into a 37°C water bath and dropping 
200 l of either sample or negative control cells (appr. 1x106 cells) on the centre of 
each slide. Negative controls have been incubated at +37°C for 5 minutes, before 
being fixed by adding 200 l 8%PFA and incubating at room temperature for 10 
minutes. Finally, PFA was removed by two washes in PBS. Samples were activated 
in the same way, however, a kinetics was performed by incubating cells on anti-CD3 
and –CD28 coated coverslips for 3,5 and 7 minutes before fixing them with PFA. 
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3.8.3. Immunofluorescence staining 
 
Following two washes in PBS, coverslips were incubated for 10 minutes in 
50mM NH4Cl, followed by two additional washes in PBS. NH4Cl treatment is required 
to quench unreacted aldehydes and prevent covalent binding of staining antibodies 
to proteins. Subsequently, cells were permeabilized before proceeding with 
intracellular staining against phosphorylated SLP76 (Y128) and LAT (Y191). Cells 
were incubated for 15 minutes in permeabilization buffer containing 2% BSA, 0.05% 
Saponine in PBS. This buffer was used throughout all subsequent washing and 
antibody staining. Antibody mixture for pSLP76 and pLAT was prepared. 80 l drops 
were distributed on a flat surface as mentioned in paragraph 3.8.1.2. and coverslips 
were applied onto antibody drops with the cell-attached side facing down. After 
incubation with primary antibody for 45 minutes at room temperature, coverslips were 
washed three times then incubated for 45 minutes with secondary antibodies. Finally, 
three additional washes in permeabilization buffer were performed. To avoid fast 
bleaching of the fluorochrome-signal, a Mowiol-Dabco mixture was used as medium 
to mount coverslips on microscope glass-slides. Slides were left in the dark at room 
temperature over night, before performing analysis by confocal microscopy. (Slides 
were then stored at +4°C).  
 
3.9. In vivo tumor imaging experiment 
 
Initial experiments, aimed to evaluate the formation of lung tumors by the 
parental LLC cell line or the luciferase-transfected LLC-LUC2/1 cells, were performed 
by injecting cells in the lateral tail vein of recipient mice. Cells were detached using 
trypsin and washed twice in PBS, then resuspended in PBS and mixed in a 1:1 ratio 
(LLC:LLC-LUC2/1). For all injections cell concentration was 5x 106/ml. Four C57BL/6 
and four S376A mice were injected with 200 l (appr. 1x 106 cells) of the LLC:LLC-
LUC2/1 – mixture. In parallel, two control injections were performed in order to 
compare the tumorigenic potential of LLC-LUC2/1 with that of untransfected LLC 
cells. For control group 1, three C57BL/6 mice were injected with LLC cells only, 
whereas in control group 2 three mice were injected with LLC LUC2/1 cells only. For 
both groups we injected 1x 106 cells in 200 l PBS. To confirm engraftment in lungs 
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for mice, which were injected with LLC-LUC2/1 luminescence, emission was 
measured one hour after injection. Mice were sacrificed 26 days post injection and 
lungs were analysed for the presence of tumor foci. In order to be able to monitor 
cancer growth in vivo, mice were anesthetized and luciferin had to be injected into 
mice intra peritoneal (IP). Luciferin serves as substrate for luciferase, triggering 
immediate luminescence, which can be measured by an IVIS Lumina CCD camera 
(Xenogen/Caliper).  
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4. Results 
 
4.1.1. Activation-induced phosphorylation in SLP76-S376A knock-in mouse 
 
T-cell stimulation triggers immediate activation of various intracellular signaling 
cascades. Activation-induced signaling is mainly carried out by changes in protein 
posttranslational modifications. Undoubtedly, the SLP76-LAT scaffold-complex plays 
a crucial role in TCR-dependent signal transduction, providing a platform for the 
recruitment of several downstream effectors of T-cell signaling (Koretzky et al., 
2006). 
Based on our previous work on human T-cell lines and primary T-cells, we 
expected that expression of the SLP76-S376A mutant would drive increased 
signaling and activation in T-cells from knock-in mice compared to control T-cells 
form C57Bl/6 mice. To test this prediction, we first decided to monitor 
phosphorylation of well-known markers of activation such as the Erk1 and Erk2 
protein kinases (Chow et al., 2001). Indeed, activation of these enzymes is 
highlighted by the phosphorylation of critical Thr and Tyr sites in the catalytic domain 
that can be detected by phosphospecific antibodies. For these experiments, T-cells 
were activated by cross-linking the TCR complex and the co-stimulatory protein 
CD28. This was obtained by incubating cells with biotinylated antibodies against CD3 
and CD28 followed by streptavidin, which binds biotiniylated proteins with high 
affinity, thus leading to their aggregation (Levine et al., 1997). 
Changes in activation-dependent phosphorylation might indicate important 
differences in CD4+ and/or CD8+ T-cell activation. Regarding these effects under the 
perspective of a whole organism, such differences may reveal relevant physiological 
consequences. 
 
In an initial set of experiments, activation-induced Erk phosphorylation was 
detected by flow cytometry (FCM) in cells obtained from mouse spleen (Figure 14). 
Relevant lymphocyte populations were identified based on their size (FSC) and 
granularity (SSC) features (Figure 14A) and specific staining with CD8 (Figure 14B) 
or CD4 (Figure 14C) antibodies, labeled with different fluorochromes. Cell fixation 
and permeabilization allowed us to detect intracellular Erk1/2 phosphorylation in 
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gated CD4- or CD8-positive cells using phosphosite-specific antibodies coupled to a 
third fluorochrome (Figure 14D-G). When necessary, appropriate compensations 
were applied during data acquisition and/or analysis to correct for the spillover 
emission of each fluorochrome in different spectral channels. For instance, specific 
phospho-ERK1/2 detection without significant increase of CD4 or CD8 signal is 
shown in Figure 14E and 14G. 
Phospho-Erk1/2 signal was induced in cells stimulated by PMA (Figure 14E 
and G) or CD3/CD28 cross-linking (Figure 15) but virtually undetectable in resting 
cells (Figure 14D, 14F and 15).  
  
 
 
 
 
Figure 14 
Flow cytometry experiment, Gating strategy. A) Selection of lymphocyte population based on size 
(FSC) and granularity (SSC) features, B) CD8+ T-cell analysis within the lymphocyte population gate, C) 
A B C 
D E 
unstimulated unstimulated unstimulated 
unstimulated +PMA 
unstimulated +PMA 
G F 
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CD4+ T-cell analysis within the lymphocyte population gate. D) Intracellular staining of ERK 
phosphorylation in unstimulated CD4+ T cells (negative control). E) Intracellular staining of ERK 
phosphorylation in PMA-treated CD4+ T cell population (positive control). F) Intracellular staining of 
ERK phosphorylation in unstimulated CD8+ T cells. G) Intracellular staining of ERK phosphorylation in 
PMA-treated CD8+ T cells. 
 
Erk phosphorylation in CD4+ and CD8+ T-cells is shown as histograms in 
Figure 15, with each curve representing to one kinetic time point. The brown 
histogram at front resembles the positive control performed by stimulatin cells with 
with PMA. Histograms allowed to rapidly appreciating the modifications in ERK 
phosphorylation in stimulated cells. However, plotting the geometric mean of phosho-
ERK signal in Figure 16, gave a quantitative view of the differences in ERK activation 
between T cells from wild type C57Bl/6 (Bl6) mice and SLP76-S376A knock-in mice 
(SA). We found that ERK phosphorylation was slightly but consistently increased in 
both CD4+ and CD8+ T cells from SLP76-S376A knock-in mice as compared to wild-
type cells. These data suggested that mutation of 14-3-3 binding site on SLP76 lead 
to increased TCR-dependent signalling in T cells, in agreement with our previous 
work. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15 
Flow cytometry experiment, histogram analysis of Erk phosphorylation. CD4+ T-cells were 
stimulated using anti-CD3 and anti-CD28 antibodies. Each histogram represents one time point of the 
applied kinetics, shown as follows: 0 min (red), 1.5 min (blue), 3 min (green), 6 min (orange), 10 min 
(light blue), 15 min (pink). Histogram for PMA positive control is shown in brown. C57BL/6 mice (B6) 
are shown on the left panel and SLP76-S376A mutant mice (SA) on the right panel. 
 
B6 CD4 SA CD4 
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Figure 16 
Flow cytometry experiment, analysis of Erk phosphorylation. Erk phosphorylation kinetic curves are 
shown in blue for C57BL/6 mice (B6) and in red for SLP76-S376A mutant mice (SA). CD4+ T-cells are 
shown on the left panel (A) and CD8+ T-cells on the right panel (B). Stimulation was performed as 
mentioned in Figure 15. Time of stimulation is indicated on the x-axis whereas the y-axis indicates 
the geometric mean . 
 
4.1.2. Analysis of SLP76 and ERK phosphorylation by western blotting 
 
In order to confirm the results obtained by FCM using an alternative approach, we 
analyzed activation-induced phophorylation of ERK kinases using Western Blot as 
readout. For these experiments, we purified CD4+ and CD8+ T-cells from a pool of 
mouse splenocytes and lymph node cells to increase the total cell recovery. In 
parallel to ERK phosphorylation, we also analyzed SLP76 tyrosine phosphorylation. 
Indeed, we previously showed that Jurkat cells, phosphorylation of residue Y128 was 
increased when SLP76-S376A was expressed in Jurkat cells (Di Bartolo et al., 2007), 
Intensity of phosphorylated ERK and SLP76 bands was quantified and data were 
normalized by the amount of 14-3-3 in each lane. In some experiments, tubulin 
amount was used as a loading control for normalization, with identical results (data 
not shown). Representative western blots are shown for CD4+ and CD8+ T-cells in 
Figure 17. The graphs in Figure 18 and 19 show a comparison of the quantified 
values in either cell type from C57Bl/6 wild-type mice and SLP76-S376A mice. 
Concerning Erk, an increase in phosphorylation was observed in both CD4+ and 
CD8+ T cells from SLP76-S376A knock-in mice compared to controls (Fig. 18). 
These results were in line with our FCM experiments (see Fig. 16) although slight 
differences in the phosphorylation kinetics were sometime apparent when comparing 
the two techniques. On the contrary, the results concerning SLP76 (Y128) 
A B 
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phosphorylation (Fig. 19) were less consistent between experiments. We obtained 
different results in CD4+ and CD8+ T cells. Indeed, at late time points (5 and 10 
minutes) SLP76 phosphorylation appeared to be stronger in SLP76-S376A cells 
compared to control CD4+ T cells. On the other hand, for CD8+ T-cells there was an 
increase of SLP76 (Y128) phosphorylation in wild-type mice compared to the mutant. 
We do not know whether these discrepancies are due to technical issues or to 
difference between these two cell types. Nonetheless, these results differ from our 
previous observation in Jurkat cells (see above) suggesting possible differential 
effects of S376 mutation in mouse vs human T cells. Further experiments are 
required to address these points. 
 
 
 
 
Figure 17 
Western blot analysis of Erk and SLP76 phosphorylation. Wild type (C57BL/6) and SLP76-S376A 
(S376A) mutant CD4+ and CD8+ T-cells were stimulated using anti-CD3 and anti-CD28 antibodies. 
CD4+ T-cells are shown in the upper panel (A) and CD8+ T-cells in the lower panel (B). Stimulation 
kinetics: 0 min, 1.5 min, 3 min, 5 min, 10 min. 14-3-3 protein was used as total protein amount 
control. 
 
 
A 
B 
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Figure 18 
Quantification of Erk phosphorylation kinetics by Western blot. Wild type (light blue) and SLP76-
S376A mutant (red) CD4+ and CD8+ T-cells were stimulated using anti-CD3 and antiCD-28 antibodies. 
CD4+ T-cells are shown in the left panel (A) and CD8+ T-cells in the right panel (B). Stimulation 
kinetics: 0 min, 1.5 min, 3 min, 5 min, 10 min. pErk data were normalized by the amount of 14-3-3 
protein in the same sample. (see Fig. 17). 
 
 
   
 
Figure 19 
Quantification of SLP76 Y128 phosphorylation kinetics by Western blot. Wild type (light blue) and 
SLP76-S376A mutant (red) CD4+ and CD8+ T-cells were stimulated using anti-CD3 and anti-CD28 
antibodies. CD4+ T-cells are shown in the left panel (A) and CD8+ T-cells in the right panel (B). 
Stimulation kinetics: 0 min, 1.5 min, 3 min, 5 min, 10 min. pSLP76 data were normalized by the 
amount of 14-3-3 protein in the same sample. (see Fig. 17). 
 
 
 
A B 
A B 
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4.2. Cytokine production upon activation of lymph node cells 
 
In paragraph 4.1., we focused our investigation to changes observed in early 
activation events. The observed increase in ERK phosphorylation in cells expressing 
SLP76-S376A might affect several T-cell functions, e.g. gene expression, cell 
communication, survival, proliferation and maturation (Roovers and Assoian, 2000). 
In order to verify whether this was the case, we compared the activation-induced 
production of cytokines by lymph node T-cells from wild type and mutant mice. Cells 
were prepared and stimulated for 6 hours as mentioned in paragraph 3.7.2. . 
Subsequent CD8 and CD4 receptor surface staining coupled to INF-γ or IL-2 
intracellular staining enabled us to observe activation-induced and population-
specific expression of these cytokines. Our gating strategy, SSC/FSC- and CD8/CD4 
dot plots for INF-γ and IL-2 detection experiments, are shown in Figure 20A and B. 
Regarding T-cells, INF-γ is known to be produced by CD4+ type 1 helper 
(Th1) cells and cytotoxic CD8+ T-cells (Bogen et al., 1993; Ghanekar et al., 2001) 
and has antiviral, immunoregulatory, and anti-tumor properties. On the other hand, 
IL-2 is expressed by different CD4+ and CD8+ T-cell subsets and affects T-cell 
growth and differentiation (Kish et al., 2005; Smith, 1988). As shown in Figure 20C-F, 
there was a striking increase of INF-γ production by CD8+ T-cells from SLP76-S376A 
mutant mice, compared to C57Bl/6 wild type animals. The comparison between wild 
type and mutant CD4+ T-cells suggested no significant differences concerning IL-2 
production as presented in Figure 20G-J. Taken together, this data suggests a 
possible CD8+ T-cell specific effect for the SLP76-S376A mutant concerning INF-γ 
cytokine production. Given the role of IFN-γ in cellular responses, the observed two-
fold increase in INF-γ secretion by SLP76-S376A CD8+ T cells is potentially relevant 
for anti-tumor and/or anti-viral immunity (Barth et al., 1991; Guidotti et al., 1999). This 
hypothesis needs to be addressed in future experiments. 
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Gating strategy: 
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CD4 IL-2 
 
 
 
 
Figure 20 
Flow cytometry analysis of cytokine (IL-2 and INF-γ) production. A) Gating of lymphocyte population 
based on FSC/SSC features, B) Selection of CD4+ and CD8+ T-cells within the lymphocyte population 
gated in A. C) Intracellular INF-γ staining of unstimulated wild type CD8+ T-cells (negative control). D) 
Intracellular INF-γ staining of wild type CD8+ T-cells upon anti-CD3/CD28 stimulation E) Intracellular 
INF-γ staining of unstimulated SLP76-S376A mutant CD8+ T-cells F) INF-γ intracellular staining of 
SLP76-S376A mutant CD8+ T-cells upon anti-CD3/CD28 stimulation G) Intracellular IL-2 staining of 
unstimulated wild type CD4+ T-cells. H) Intracellular IL-2 staining of wild type CD4+ T-cells after anti-
CD3/CD28 stimulation I) Intracellular IL-2 staining of unstimulated SLP76-S376A mutant CD4+ T-cells 
IL-2 production. J) Intracellular IL-2 staining of SLP76-S376A mutant CD4+ T-cells after anti-CD3/CD28 
stimulation. 
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4.3. T-cell proliferation assay 
 
This experiment was performed to assess proliferation rate of CD4+ and CD8+ 
T-cells, in C57BL/6 compared to SLP76-S376A mutant mice. Interestingly, T-cells 
show increased proliferation in the HPK1 knockout mice (Shui et al., 2007). To test if 
SLP76-S376A mutant mice have a similar phenotype, we performed a CFSE-based 
proliferation assay (as mentioned in 3.7.3.) using lymph node (LN) cells. LN cells of 
C57BL/6- and SLP76-S376A-mice were isolated and stained with CFSE. 
Subsequently, LN cells were activated on anti-CD3 + anti-CD28 pre-coated plates for 
72 hours. Non-stimulated control cells for both mutant and wild type were kept in 
culture medium without stimulatory antibodies. Thereafter, LN cells were stained with 
antibodies directed against CD4- and CD8 receptors to allow further cell proliferation 
analysis of these two populations by flow cytometry. Figure 21A-C shows the gating 
strategy; Figure 21C refers to the whole population gate and not to the blast cell gate. 
CFSE is a protein-labeling agent, which is detectable by flow cytometry. In each 
proliferation cycle the cells synthesize new proteins, thus, diluting CFSE-labeled 
proteins. Conversely, non-activated control cells do not divide; hence they exhibit a 
high CFSE signal, as shown in histograms in Figures 21D, F, H and J for wild type 
and mutant, respectively. Activation of T-cells triggers their proliferation therefore 
CFSE signal decreases with every proliferation cycle, as shown in Figures 21E, G, I 
and K for wild type and mutant, respectively. The bars in Figures 21D-K indicate the 
percentage of non-proliferating and proliferating cells. Evidently, there is a higher 
percentage of proliferating CD4+ and CD8+ mutant T-cells compared to wild type. 
This difference was more evident when the analysis was performed by gating on 
blast cells (e.g. activated cells with increased size), as shown in Figure 22A and B. 
Interestingly, this analysis reveals that a fraction of mutant T-cells performed at least 
an additional proliferation cycle compared to wild type T-cells. In conclusion, this 
assay demonstrates increased T-cell proliferation for the SLP76-S376A mutant. 
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CD8+ T-cells 
 
 
 
 
 
Figure 21 
Analysis of lymph node T-cell proliferation by CSFE dilution assay. A. Gating on whole lymph node 
cell population (outer pink region) or on blast (higher size) cells (inner pink region) in non-stimulated 
wild type control, B. Whole cell and blast gating in stimulated wild type lymph node cells, C. Selection 
of CD4+ and CD8+ T-cell population within the total lymphocyte population. D to K. Histograms 
showing CFSE labeling of the following gated cell populations: unstimulated, wild type CD4+ T-cells 
(D); activated wild type CD4+ T-cells (E); unstimulated SLP76-S376A CD4+ T-cells (F); activated SLP76-
S376A CD4+ T-cells (G); unstimulated wild type CD8+ T-cell (H); activated wild type CD8+ T-cells (I); 
unstimulated SLP76-S376A CD8+ T-cells (J); activated SLP76-S376A CD8+ T-cells (K). The percentage 
of not dividing vs proliferating cells (defined by the left and right black bars, respectively) is indicated 
in each graph. 
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CFSE dilution assays analysis by gating on blast cell population  
 
 
Figure 22 
Analysis of T-cell proliferation by CSFE dilution assay on gated T-cell blast. CD4+ and CD8+ T-cells 
blasts were gated as shown in Fig. 21. CFSE signal of wild type and SLP76-S376A mutant T-cells is 
represented in histograms. CD4+ T-cells are shown in the left panel (A) and CD8+ T-cells in the right 
panel (B). Activated wild type and SLP76-S376A mutant T-cells are shown in blue and red, 
respectively. Non-activated wild type and SLP76-S376A mutant T-cells are shown in black and grey, 
respectively. 
 
 
4.4. T-cell development in SLP76-S376A knock-in mice 
 
Concerning T-cell development, in SLP76-deficient mice a maturation arrest at 
the double negative stage has been reported, rendering these mice devoid of mature 
T-cells (Clements et al., 1999). Thus, SLP76 plays an important role in T-cell 
development. For this reason, we conducted an analysis of T-cell maturation. 
First, we analyzed the frequency of the major thymus specific sub-populations, 
namely double negative (DN)-, CD4 positive (CD4 pos)-, CD8 positive (CD8 pos)-, 
and double positive (DP) cells. A statistical analysis of wild type and SLP76-S376A 
knock-in mice revealed no significant differences.  
We then stained thymocytes with specific surface markers, which are 
differentially expressed during T-cell development. CD3-receptor expression is 
gradually increased as a T-cell matures, whereas CD24 surface expression 
decreases as T-cells advance in their maturation process (Bonifacino et al., 1990; 
A B 
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Kay et al., 1991). Additionally, CD4- and CD8 receptor labeling enabled us to monitor 
CD3 and CD24 expression in the four thymic sub-populations mentioned above.  
Figure 23A and B represent a thymus lymphocyte population in an SSC/FSC 
dot plot and after CD4/CD8-labeling, respectively. For each sub-population (CD4 
pos, CD8 pos, DN and DP), expression of CD3 is indicated in a histogram in Figure 
23 (C-F) and for CD24 in Figure 23 (G-J). Despite occasional variations in the DN 
population, in summary no significant differences were observed in mutant mice 
concerning these markers. These results are in accordance with observations made 
for T-cell development in the HPK1 knockout mice, where no alterations have been 
described. 
 
Gating strategy: 
 
 
 
 
 
 
CD3 expression 
 
 
 
A B 
C D E F 
Legend for Figures C-J: 
wt = wild type 
SA = SLP76-S376A mutant 
CD4 CD8 DN DP 
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CD24 expression 
 
 
Figure 23 
Analysis of expression of T-cell developmental markers, CD3 and CD24, by flow cytometry.  
A. Gated thymocyte population; B. Selection of CD4+, CD8+, DN and DP T-cell population within the 
thymocyte population shown in A. C-J. The expression of CD3 as well as of CD24 is represented in 
histograms; orange and green lines indicate expression of either marker in wild type samples, 
whereas blue and red indicate expression in SLP76-S376A thymocytes. CD3 expression is shown for 
the following thymic subpopulations:  CD4+ cells (C); CD8+ cells (D); DN cells (E); DP cells (F). CD24 
expression is shown for the following thymus subpopulations: CD4+ cells (G); CD8+ cells (H); DN cells 
(I); DP cells (J).  
 
4.5.  Confocal microscopy experiments to detect possible alterations of 
microcluster formation in SLP76-S376A mice 
 
The aim of this experiment was analyzing the effect of the S376A mutation on 
the assembly of signaling MCs and their stability in mouse T-cells. Using human T-
cell lines and primary T-cells, the laboratory has previously shown that this mutation 
increases the stability of MCs. Indeed, based on the proposed model, 
phosphorylation by HPK1 and 14-3-3 binding to SLP76 would be abolished by 
mutating S376, thus leading to a stabilization of SLP76 binding to pLAT-containing 
MCs (Lasserre et al., 2011). 
Purified CD4+ or CD8+ T-cells were activated by incubation on glass 
coverslips, pre-coated with anti-CD3 and anti-CD28 antibodies. Engagement of T-
cells with these stimulatory antibodies would mimic an interaction between a T-cell 
and an APC, which allows visualizing of signaling MCs with high spatial resolution. 
MC formation has been monitored at various time points up to 7 minutes of 
stimulation. MCs could be visualized by immune-fluorescence staining of MC-
G H I J 
CD4 CD8 DN DP 
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integrated proteins, which can then be detected by confocal microscopy. Hence, 
antibodies directed against pSLP76 and pLAT (two major components of MCs), were 
used to visualize MC-formation.  
Quantification of MCs was performed using a script written using the “Acapella 
High Content Imaging And Analysis Software”. This script allows an automated 
quantification of the number of MCs per cell and their signal-intensity (Figure 25). 
Statistical analysis of quantification was carried out by performing an unpaired 
student t-test (confidence intervals 95%), using Prism (GraphPad Software, Inc. 
USA). Unfortunately, due to a cross-reactivity of the secondary antibody used to 
detect anti-pSLP76 antibody (raised in mouse) with the activating anti-CD3 antibody 
(raised in Armenian hamster), a high background was observed all over the surface 
of pSLP76-labeled coverslips (data not shown). 
Figure 24A and B show the number of pLAT-containing MCs in CD4+ and 
CD8+ T-cells, respectively. A significant increase in the number of MCs per cell was 
found in mutant CD4+ T-cells; however no significant differences were obtained for 
CD8+ T-cells. In agreement with our hypothesis, these results suggest a higher MC 
stability in mutant CD4+ T-cells. Unexpectedly, this was not the case for the CD8+ T-
cell population, where MCs of wild type and mutant seem to be equally stable. 
However, CD8+ T-cells appeared to be smaller and in lower abundance than CD4+ T-
cells, therefore, changes in the acquisition or analysis settings may be required. 
Moreover, cell activation protocols are established for a CD4+ Jurkat cell line, hence, 
adjustments for efficient activation of CD8+ T-cells on coverslips might be necessary. 
Further experiments are needed to verify this apparent lack of effect of S376 
mutation on MCs stability in CD8+ T-cells. 
 
Figure 24 
Analysis of signaling 
protein microclusters by 
confocal microscopy. 
Each plot shows the 
number of pLAT 
microclusters per cell of 
either wild type or SLP76-
S376A mutant, as 
A B 
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indicated on the X-axis. A. pLAT microclusters in CD4+ T-cells stimulated for 7 minutes. B. pLAT 
microclusters in CD8+ T-cells stimulated for 7 minutes. Statistical analyses showed a significant 
increase in the number of pLAT microclusters/cell in mutant CD4+ T-cells compared to wild-type 
controls (A), whereas no significant difference was observed for CD8 T-cells. 
 
LAT wild type 1  LAT wild type 2  LAT wild type 3 
     
LAT SLP76-S376A 1  LAT SLP76-S376A 2  LAT SLP76-S376A 3 
    
Figure 25 
Microcluster imageing in CD4+ T-cells. Upper panels (LAT wild type 1,2,3) show three example 
images of wild type CD4+ T-cells stimulated for 7 minutes. Lower panels (LAT SLP76-S376A 1,2,3) 
shows three example images of wild type CD4+ T-cells stimulated for 7 minutes. A slight but 
significant increase in microclusters per cell for SLP76-S376A mutant T-cells is visible. For preparation 
of sample images shown in this figure we used Image J (Ref: Abramoff. M.D.. Magalhaes, P.J.. Ram 
S.J. ”Image Processing with Image J”. Biophotonics International volume 11, issue 7, pp. 36-42.2004) 
software. 
 
4.6. Set-up of in vivo tumor growth imaging 
 
This experiment was set up to determine if disruption of the 14-3-3-SLP76-
interaction is involved in T-cell mediated tumor rejection. 
Lewis lung carcinoma (LLC) cells form lung tumors in mice. However, HPK1 
knockout mice have been reported to reject tumors when challenged with LLC 
(Alzabin et al., 2010). HPK1 triggers a negative feedback loop shutting down T-cell 
activation. As explained previously, a putative mechanism involves phosphorylation 
of SLP76 at S376 by HPK1 and consequent binding of 14-3-3 proteins to SLP76 
(Lasserre et al., 2011; Shui et al., 2007). As explained above, this interaction would 
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lead to disassembly of SLP76 containing signaling microclusters, thus inhibiting T-
cell activation. Hence, disruption of this negative feedback loop increases T-cell 
activation, as demonstrated in Jurkat cells.  
We decided to exploit the SLP76-S376A knock-in mice to address whether 
disruption of the HPK1-dependent binding of 14-3-3 proteins to SLP76 may alter the 
ability of CD8+ T-cells to reject LLC tumors. To this aim, we generated LLC-LUC2/1 
cells, a clone of LLC transfected with a luciferase reporter vector, allowing for easier 
detection of tumor cells in vivo. To test the suitability of this experimental model, we 
conducted pilot experiments by injecting LLC-LUC2/1 cells in wild-type mice. Mice 
were monitored for 30 days. Administering luciferin by intraperitoneal injection 
allowed visualizing tumors immediately in anesthesized mice. Luciferase-dependent 
photon emission was detected (Figure 26, left panel) and quantified (Fig. 26, upper 
right panel) by a CCD camera. These data showed the presence of luminescent 
tumor cells in chest and/or abdomen of LLC-LUC2/1-injected mice but not control 
animals receiving non-transfected tumor cells. Subsequently, lungs were explanted 
and incubated with luciferin in vitro. Imaging with the CCD camera demonstrated the 
presence on luminescent tumor cells in the lungs of LLC- LUC2/1-injected but not 
control mice (Fig. 26, lower right panel). However, tumor growth was also detected in 
spleen and intestine of these animals (data not shown). 
Although the presence of tumor growth outside the lungs was unexpected, 
these data demonstrate that the LLC-LUC2/1 cell line constitutes a valuable tool to 
study tumor development and anti-tumor immune responses in mice. 
Figure 26 
In vivo tumor growth imaging using 
LLC cells transfected with a 
luciferase reporter gene. Mice were 
injected i.v. with LLC cells expressing 
the luciferase gene. Luciferase-
dependent photon emission was 
detected by a CCD camera (left 
panel). Quantification of photon 
emission from live animals (upper 
right panel) or from explanted lung 
(lower right panel) is shown.
Imaging by 
CCD camera 
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5. Discussion  
 
The initial aim of this work was to characterize T-cell development and 
function in SLP76-S376A knock-in mice. Based on previous results of the laboratory, 
this mutation was expected to result in increased TCR-dependent signaling that may 
potentially alter thymic development and/or peripheral T-cell responses. (Di Bartolo et 
al., 2007; Lasserre et al., 2011)  
The work performed during my Master thesis suggests that the SLP76-S376A 
does not induce major changes in thymic T-cell development. For instance, my 
experiments demonstrated equal distribution of thymus subpopulations (DN, DP, 
CD8+ and CD4+) in wild type and mutant mice. Furthermore, analysis of expression 
of developmental markers, such as CD3 and CD24, revealed no significant changes 
in T-cell development. In order to detect possible defects concerning early thymocyte 
maturation, we used CD25 and CD44 as markers for dissecting the development of 
DN populations (DN1, DN2, DN3 and DN4). So far, this analysis has not revealed 
significant differences between control and mutant mice (data not shown). Despite no 
proven significance, we noticed in some experiments slight differences in CD3 and 
CD24 expression, especially regarding the DN population. It is unclear whether these 
differences reflect variability in marker expression between individual animals or are 
consequences of the expression of SLP76-S376A. Therefore, we plan to repeat 
these experiments in order to verify and support our statistical analysis. Further 
analyses will be performed after crossing the SLP76-S376A mice with TCR-
transgenic mice that may unmask slight effects on thymic development induced by 
the mutation. Other described developmental markers, e.g. NUR77, whose 
expression is dependent on the strength of TCR signaling (Cunningham et al., 2006), 
will be used to further define possible developmental aberrations.  
I also conducted experiments to analyze signaling and functional responses by 
mature T-cells. Erk-1 and -2 MAP-kinases phosphorylation is a known marker of T-
cell activation. Lack of phosphorylation of S376 residue may result in increased 
ERK1/2 activation, as previously observed for HPK1-deficient T-cells (Shui et al., 
2007). Our experiments provide evidence for similar findings in our SLP76-S376A 
mouse model. Mutant CD4+ and CD8+ T-cells, showed augmented Erk1/2 
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phosphorylation upon TCR stimulation, therefore indicating increased 
responsiveness to activation compared to wild type cells. These observations were 
made by flow cytometry analysis and subsequently confirmed by western blot 
experiments. However, analysis of other activation markers, as for instance 
phosphorylation of SLP76 Y128 residue, did not give so far conclusive results. 
Indeed, increased phosphorylation of this residue was observed when an SLP76-
S376A mutant was expressed in Jurkat cells (Di Bartolo et al., 2007). Different 
kinetics of SLP76 Y128 phosphorylation in murine T-cells as compared to Jurkat cells 
and human primary T-cells might explain the differences observed in the different 
models. Alternatively, these apparent discrepancies may be due to the different 
stimulatory conditions used. Indeed, while previous experiments where performed by 
stimulating T cells with anti-CD3 antibodies (Di Bartolo et al., 2007), the results 
shown here were obtained after anti-CD3 and –CD28 antibody cross-linking, a 
procedure resulting in more efficient mouse T-cell activation. These potential 
explanations need to be addressed by further experiments. Additional investigations 
about other early T-cell activation markers will be also performed.  
Increased TCR-dependent signaling may affect survival and proliferation of T-
cells. Here, we demonstrated an increased proliferation rate for CD4+ and CD8+ 
mutant T-cells compared to wild type. Hence, we propose that lack of HPK1-
mediated negative regulation in mutant T-cells is responsible for these differences in 
proliferation rates. This effect was more evident when performing the CFSE dilution 
analysis by gating specifically on cells with higher forward scattering, which include 
activated T-cells with increased size (i.e. blasts). We observed that a higher 
percentage of blast cells in the mutant have reduced levels of CFSE labeling 
compared to wild type, suggesting an increased proliferation of the former. However, 
we cannot rule out that these data reflect an increased resistance of mutant T cells to 
activation-induced cell death (Brenner et al., 2005). Further experiments need to be 
performed to confirm these data and address the underlying cellular mechanism.  
Cytokine production assays were performed to further explore the 
consequences of increased responsiveness of SLP76-S376A T-cells. We analyzed in 
particular the production of IL-2 and INF-γ by in vitro-stimulated control and mutant T-
cells. Whereas these studies did not reveal significant differences in IL-2 production, 
we observed a two fold increase of INF-γ production by mutant T-cells. INF-γ is a 
pro-inflammatory cytokine (type 2 class Interferon), which exerts immunostimulatory 
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and immunomodulatory effects e.g. activation of macrophages, NK cells and 
cytotoxic CD8+ T-cells (Schroder et al., 2004). NK cells and cytotoxic CD8+ T-cells 
are effector cells important for anti-tumoral and anti-viral activity. Hence, increased 
production of INF-γ by T-cells may improve multiple functions of these cells and 
boost immune responses. It will be interesting to determine whether INF-γ production 
is increased in other hematopoietic cell types (e.g. NK cells) that also express SLP76 
and to define the functional consequences of this modification on immune responses. 
These results suggest that SLP76-S376A expression induce a specific effect on INF-
γ production, although it is currently unclear how the mutation of SLP76 may affect 
signaling pathways controlling IFN-γ but not IL-2 production. IL-2 is important for T-
cell development but also for survival, proliferation, growth and differentiation of T-
cells (Boyman and Sprent, 2012). Thus, further experiments will have to be 
performed to confirm this data and possibly investigate the molecular control of 
selective cytokine production by SLP76.  
Altogether, the functional modifications detected in SLP76-S376A T-cells are 
reminiscent of the phenotype displayed by HPK1 knockout mice. HPK1-deficient T-
cells show a higher proliferation rate, as well as augmented IL-2 production (Shui et 
al., 2007). Interestingly, an inverse correlation between HPK1 expression and INF-γ 
production has been reported for human CD4+ T-cells (Zhang et al., 2011). To our 
knowledge, the effect on INF-γ production has not yet been described in HPK1 
knock-out mice. However, HPK1 deficient mice were reported to exhibit increased T-
cell mediated anti-tumor activity (Alzabin et al., 2010), therefore we decided to set up 
a bioluminescence based assay, which would enable us to quantify tumor growth in 
vivo. This tumor growth assay was performed using LLC cells, which produce large 
amounts of prostaglandin E2 (PGE2). PGE2 is a naturally occurring lipid compound 
that among a variety of different functions also acts as regulator of inflammation 
(Kalinski, 2012). According to the literature, PGE2 can activate HPK1 by a cAMP-
dependent pathway but the molecular mechanism of how HPK1 exerts its negative 
regulation of anti-tumor immunity is not well understood. We propose a model where 
PGE2-mediated activation of HPK1, affects T-cell activity by enforcing HPK1-
mediated phosphorylation of SLP76 and negative regulation of T-cell signaling and 
activation. Since our mouse model is defective for this negative regulatory pathway, it 
is a suitable tool to challenge our model. If our hypothesis is valid, SLP76-S376A 
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mice should show higher resistance against the PGE2-induced immune suppressive 
effects.  
CD8+ T-cells are effector cells that are able to induce apoptosis in target cells, 
e.g. tumor cells, by different mechanisms. PGE2-induced inhibition of T-cell 
activation might impede these T-cell effector mechanisms, however, on the cell 
biological level very little is known. The formation of a cytolytic synapse between a T-
cell and a target cell is crucial for efficient target cell killing. A sequence of specific 
events implying TCR-signaling, recruitment and activation of adhesion molecules, 
cytoskeleton rearrangements, eventually leads to secretion of cytotoxic granules and 
apoptosis induction (Jenkins and Griffiths, 2010). Interestingly, both HPK1 and 
SLP76 may modulate several of these events (Koretzky et al., 2006; Patzak et al., 
2010; Shui et al., 2007). Moreover, Erk phosphorylation has been implicated in 
regulating the delivery of cytolytic granules to the cytolytic synapses (Chen et al., 
2006). As mentioned above, HPK1 as well as our SLP76-S376A mutant show higher 
levels of Erk phosphorylation that, in principle, might affect the formation of a cytolytic 
synapse. This hypothesis may be addressed by conducting further confocal 
microscopy experiments. It will be interesting to address whether PGE2 may affect 
cytolytic synapse formation and/or function by altering the pathways mentioned 
above.  
LCK as well as ZAP70 are essential tyrosine kinases involved in early TCR-
signaling. Their activity also contributes to efficient cytolytic synapse formation.  LAT 
and SLP76 are two major scaffold proteins of signaling complexes and are both 
substrates of ZAP70. Increased phosphorylation of these proteins and higher stability 
of signaling microclusters were recently demonstrated in human T cells upon HPK1 
knockdown or expression of SLP76-S376A (Lasserre et al., 2011). Hence, I tried to 
verify whether this was also the case in mutant mice, since it could explain the 
observed increase in downstream signaling. Several difficulties with the set up of 
microcluster visualization with mouse T-cells by confocal microscopy, made it difficult 
to analyze obtained data. Moreover, we need to reconfirm these experiments by 
adding more time points to our kinetics. Nevertheless, at late stimulation time points 
(e.g. 7 minutes), I observed some increase in the stability of pLAT microclusters in 
CD4+ T-cells from the SLP76-S376A mice. I performed similar experiments with 
CD8+ T-cells, but no alterations of microcluster stability could be detected in this 
case. However, due to the reduced size of CD8+ T-cell compared to CD4+ T-cells, 
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detection of microclusters in the former will require further optimization. The results I 
obtained so far do not provide data with statistical significance; hence they need to 
be repeated. Possible modification of the detection settings may be of help for 
increasing the detection of microclusters per cell (e.g. acquiring images at higher 
zoom values compared to those used for CD4+ T-cells).  
In summary, the results obtained so far indicate that SLP76-S376A mutant 
expression in mice induces no developmental alterations, whereas mutant T-cells 
exhibit increased signaling, higher cell proliferation rate and increased production of 
selected cytokines for CD8+ T-cells upon TCR induction. Moreover, the tools I 
generated during my Master Thesis will allow future investigations about the role of 
the HPK1-mediated negative regulation of T-cell activation in T-cell-dependent anti-
tumor immunity. Elucidating further functions of HPK1 may eventually lead to hints 
for novel HPK1-targeted cancer immunotherapy (Sawasdikosol et al., 2012).  
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Zusammenfassung 
 
Die Interaktion zwischen (SRC homology 2 (SH2)-domain-containing 
leukocyte protein of 76 kDa) SLP76 und (Hematopoietic progenitor kinase1) HPK1 ist 
essentiell für eine erst kürzlich entdeckte Negativ-Regulation der T-Zell-Aktivierung. 
Es wurde gezeigt, dass eine einzige Punktmutation in SLP76 (S376A), die 
Phosphorylierung dieses Proteins durch HPK1 verhindert und somit die Negativ-
Regulation beeinträchtigt. Folglich, sind reagieren T-Zellen dieser Mutante senitiver 
auf aktivierende Stimuli. 
SLP76 ist eine Hauptkomponente einer sich, bei T-Zell Rezeptor Stimulation, 
bildenden Signaling-Plattform. Zahlreiche Prozesse können von SLP76-mediiertem 
Signaling beeinflusst werden wie z.B.: Zell-Proliferation, -Survival, -Maturation und 
Differenzierung. SLP76 ist darüber hinaus bekanntlich essentiell für T-Zell 
Entwicklung. 
Ein SLP76-S376A Mausmodell wurde generiert um die physiologische 
Relevanz dieser defekten Negativ-Regulierung zu überprüfen. Diese Arbeit ist eine 
Charakterisierung eines SLP76-S376A mutanten Mousmodells, mit Fokus auf frühe 
Signaling-Events, Downstream-Effektorfunktionen und auch T-Zell Entwicklung im 
Thymus.  
In Übereinstimmung mit publizierten Daten für das HPK1 knock-out 
Mausmodell, demonstriert die SLP76-S376A Mutante keinerlei Defekte in T-Zell 
Entwicklung. Die SLP76-S376A Mutante zeigt jedoch, erhöhte Proliferationsraten 
und ERK (Extracellular signal-regulated kinase) Phosphorylierung in CD4+ und 
CD8+ SLP76-S376A T-Zellen, so wie auch inkrementierte INF-γ Produktion in 
SLP76-S376A CD8+ T-Zellen, im Vergleich zu Wildtyp T-Zellen.  
Schlussendlich präsentiert die SLP76-S376A Mutante einen Satz veränderter 
T-Zell-Eigenschaften welche von einer defekten Negativ-Regulierung, der T-Zell 
Rezeptor Aktivierung, stammen. In einem HPK1 knock-out Mausmodell wurde erst 
kürzlich verstärkte, T-Zell abhängige, Anti-Tumorimmunaktivität demonstriert (Alzabin 
et al. 2010). Aus diesem Grund habe ich eine bioluminiszente Tumorzelllinie 
entworfen, welche verwendet werden kann um die Rolle der HPK1-SLP76-Interaktion 
in Anti-Tumorimmunaktivität zu eruieren. 
 
